<PAGE>
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the registrant [X]
Filed by a party other than the registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] Confidential, for Use of the Commission Only (as permitted by Rule 14a-
6(e)(2))
[X] Definitive Proxy Statement
[_] Definitive Additional Materials
[_] Soliciting Material Pursuant to (S) 240.14a-11(c) or (S) 240.14a-12
PHP HEALTHCARE CORPORATION
-----------------------------------------------------------------------------
(Name of Registrant as Specified in Its Charter)
----------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] $500 per each party to the controversy pursuant to Exchange Act Rule
14a -6(i)(3).
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the form or schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
<PAGE>
PHP HEALTHCARE CORPORATION
11440 COMMERCE PARK DRIVE
RESTON, VIRGINIA 20191
OCTOBER 8, 1997
----------------
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
----------------
To the Shareholders of
PHP HEALTHCARE CORPORATION:
The 1997 Annual Meeting of Shareholders of PHP Healthcare Corporation (the
"Company") will be held on Monday, November 3, 1997, at 10:00 a.m. local time,
at the Company's corporate offices at 11440 Commerce Park Drive, Reston,
Virginia, for the following purposes:
1. To elect four directors for a term to expire in 2000;
2. To amend the Certificate of Incorporation of the Company (a) to increase
the authorized Common Stock from 25,000,000 shares to 100,000,000
shares, (b) to increase the authorized Preferred Stock from 500,000
shares to 10,000,000 shares and (c) to authorize the Board of Directors
to provide for the issuance of shares of Preferred Stock in one or more
series, to establish the number of shares to be included in each such
series and to fix the designations, powers, preferences, and rights of
each such series, and any qualifications, limitations or restrictions
thereof;
3. To amend and restate the Company's 1996 Incentive Plan; and
4. To transact such other business as may properly come before the meeting
or any adjournment thereof.
Holders of Common Stock of the Company whose names appear of record on the
books of the Company at the close of business on October 2, 1997, are entitled
to notice of and to vote at the meeting or at any adjournment thereof. A list
of such shareholders will be available for inspection by shareholders at the
Company's principal office for a period of ten days prior to the meeting date.
By Order of the Board of Directors
Ben Rosenbaum III
Secretary
- --------------------------------------------------------------------------------
WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING, PLEASE COMPLETE, DATE AND
SIGN THE ENCLOSED PROXY CARD AS SOON AS POSSIBLE. A POSTAGE-PAID-RETURN-
ADDRESSED ENVELOPE IS ENCLOSED FOR YOUR CONVENIENCE.
- --------------------------------------------------------------------------------
<PAGE>
PHP HEALTHCARE CORPORATION
11440 COMMERCE PARK DRIVE
RESTON, VIRGINIA 20191
----------------
PROXY STATEMENT
FOR
ANNUAL MEETING OF SHAREHOLDERS
NOVEMBER 3, 1997
----------------
GENERAL INFORMATION
This Proxy Statement is being furnished to shareholders of PHP Healthcare
Corporation, a Delaware corporation (the "Company"), in connection with the
solicitation by the Board of Directors of the Company (the "Board") of proxies
for use at the Annual Meeting of Shareholders to be held on November 3, 1997,
at the Company's offices at 11440 Commerce Park Drive, Reston, Virginia, for
the purposes set forth in the accompanying Notice of Annual Meeting of
Shareholders, and at all adjournments thereof (the "Annual Meeting"). This
Proxy Statement is first being mailed to the Company's stockholders on or
about October 8, 1997.
PURPOSES OF THE ANNUAL MEETING
At the Annual Meeting, holders of record of the Company's outstanding shares
of common stock, par value $0.01 per share (the "Common Stock"), will be asked
to consider and vote upon the following matters:
(i) To elect four directors for a term to expire in 2000 ("Proposal I");
(ii) To amend the Certificate of Incorporation of the Company (a) to
increase the authorized Common Stock from 25,000,000 shares to
100,000,000 shares, (b) to increase the authorized Preferred Stock from
500,000 shares to 10,000,000 shares and (c) to authorize the Board of
Directors to provide for the issuance of shares of Preferred Stock in
one or more series, to establish the number of shares to be included in
each such series and to fix the designations, powers, preferences, and
rights of each such series, and any qualifications, limitations or
restrictions thereof ("Proposal II");
(iii) To amend and restate the Company's 1996 Incentive Plan ("Proposal
III"); and
(iv) To transact such other business as may properly come before the Annual
Meeting.
The Board unanimously recommends that stockholders vote FOR each of the
proposals described in this Proxy Statement. As of the date of this Proxy
Statement, the Board knows of no other business to come before the Annual
Meeting.
RECORD DATE; QUORUM; VOTE REQUIRED
The Board has fixed the close of business on October 2, 1997, as the record
date for determination of the stockholders entitled to notice of, and to vote
at, the Annual Meeting (the "Record Date"). As of the Record Date, there were
11,559,930 shares of Common Stock outstanding. The presence, either in person
or by properly executed proxy, of the holders of a majority of the outstanding
shares of Common Stock as of the Record Date is necessary to constitute a
quorum at the Annual Meeting. Each share of Common Stock outstanding on the
Record Date entitles the record holder thereof to one vote on each matter that
may properly come before the Annual Meeting. The four nominees for election as
directors at the 1997 Annual Meeting who receive the greatest number of votes
cast for the election of directors at that meeting shall be directors. The
affirmative vote of a majority of the outstanding shares of Common Stock
entitled to vote thereon is required to approve the amendments to the
Company's Certificate of Incorporation, as set forth in Proposal II. The
affirmative vote of a majority of the shares of Common Stock represented in
person or by properly executed proxies is required to approve the amendment to
the Company's 1996 Incentive Plan (the "1996 Plan"), as set forth in Proposal
III.
<PAGE>
PROXIES
All shares of Common Stock that are represented at the Annual Meeting by
properly executed proxies received prior to or at the Annual Meeting and not
revoked will be voted at the Annual Meeting in accordance with the
instructions indicated in such proxies. If no instructions are indicated, such
proxies will be voted for approval of the election of the Board's four
nominees as directors of the Company. Although the Company has no reason to
believe that any of the nominees will be unwilling or unable to serve as
directors, if any of the nominees is not available for election, properly
executed proxies will be voted for the election of such substitute nominees as
may be designated by the Board of Directors.
The presence at the Annual Meeting, in person or by proxy, of the holders of
record of a majority of the shares issued and outstanding on the Record Date,
and entitled to vote, shall be necessary and sufficient to constitute a quorum
for the transaction of business. Any stockholder present (including broker
non-votes) at the Annual Meeting, but who abstains from voting, shall be
counted for purposes of determining whether a quorum exists. With respect to
the approval of Proposal II, an abstention (or broker non-vote) has the same
effect as a vote against the proposal. With respect to the approval of
Proposals I and III, abstentions or broker non-votes will have no effect on
the proposals (except for purposes of determining whether a quorum is present
at the Annual Meeting).
Any proxy given pursuant to this solicitation may be revoked by the person
giving it at any time before it is voted. Proxies may be revoked by (i) filing
with the Company, at or before the Annual Meeting, a written notice of
revocation bearing a date later than the proxy, (ii) duly executing a
subsequent proxy relating to the same shares of Common Stock and delivering it
to the Company at or before the Annual Meeting, or (iii) attending the Annual
Meeting and voting in person (although attendance at the Annual Meeting will
not in and of itself constitute a revocation of a proxy).
In an agreement dated as of January 31, 1997 with the Company, Charles H.
Robbins, the Company's former Chairman and Chief Executive Officer, and his
wife, Ellen E. Robbins, agreed to vote shares of Common Stock beneficially
owned by them, at their option, (i) in accordance with the recommendations of
the Board of Directors of the Company or (ii) pro rata in the same manner and
proportion that votes of the other stockholders of the Company have been cast.
Mr. and Mrs. Robbins have not advised the Company how they intend to vote
their shares.
The Company will bear the cost of the solicitation. In addition to
solicitation by mail, the Company will request banks, brokers and other
custodian nominees and fiduciaries to supply proxy material to the beneficial
owners of Common Stock and will reimburse them for their reasonable expenses
in so doing. Certain directors, officers and other employees of the Company,
not specially employed for this purpose, may solicit proxies, without
additional remuneration therefor, by personal interview, mail, telephone,
facsimile or other electronic means.
The Company's Annual Report to Shareholders containing the Company's
financial statements for the fiscal year ended April 30, 1997, is being mailed
with this Proxy Statement. The Annual Report does not constitute a part of the
proxy soliciting material.
2
<PAGE>
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information, as of September 22,
1997, with respect to the beneficial ownership of Common Stock by (i) each
person known to the Company to be the beneficial owner of more than 5% of its
outstanding shares of Common Stock, (ii) each director of the Company, (iii)
each executive officer named in the Summary Compensation Table and (iv) all
directors and executive officers of the Company as a group.
<TABLE>
<CAPTION>
NAME AND ADDRESS NO. OF SHARES PERCENT OF CLASS
- ---------------- ------------- ----------------
<S> <C> <C>
Charles H. Robbins............................ 1,973,458(1) 15.98%
7720 Carlton Place
McLean, VA 22102
Shamrock Investments(2)....................... 1,046,419(3) 8.69%
Charles P. Reilly
Michael E. Gallagher
2049 Century Park East,
Suite 3330
Los Angeles, CA 90067
John W. Kluge................................. 816,500(4) 7.06%
c/o Metromedia Company
One Meadowlands Plaza
East Rutherford, NJ 07073
Bosko Djordjevic and Elizabeth Keck 800,000(5) 6.92%
Djordjevic, Trustee..........................
505 S. Beverly Drive,
Suite 215
Beverly Hills, CA 90212
Jack M. Mazur................................. 727,342(6) 5.92%
11440 Commerce Park Drive
Reston, VA 20191
Michael D. Starr.............................. 425,852(7) 3.59%
11440 Commerce Park Drive
Reston, VA 20191
John P. Cole.................................. 400,000 3.46%
11440 Commerce Park Drive
Reston, VA 20191
Robert L. Bowles, Jr. ........................ 157,011(8) 1.35%
820 First Street, N.E.,
Suite LL100
Washington, D.C. 20002-4205
Frank L. Provato, M.D......................... 99,166(9) *
11440 Commerce Park Drive
Reston, VA 20191
William J. Lubin.............................. 83,000(10) *
11440 Commerce Park Drive
Reston, VA 20191
George E. Schafer, M.D. ...................... 48,684(11) *
4 Imperial Oaks
San Antonio, TX 78248
</TABLE>
3
<PAGE>
<TABLE>
<CAPTION>
NAME AND ADDRESS NO. OF SHARES PERCENT OF CLASS
- ---------------- ------------- ----------------
<S> <C> <C>
Joseph G. Mathews................................ 9,725 *
3510 Highway O
Wright City, MO 63390
Donald J. Ruffing................................ 8,503 *
11104 Woodlawn Boulevard
Upper Marlboro, MD 20772
Paul T. Cuzmanes................................. 4,956 *
250 West Pratt Street
Baltimore, MD 21201
Jerry W. Carlton................................. 0 *
610 Newport Center Drive,
Suite 1700
Newport Beach, CA 92660
John J. McDonnell................................ 0 *
11440 Commerce Park Drive
Reston, VA 20191
All directors and executive officers
as a group (13 persons)......................... 2,150,763 16.34%
</TABLE>
- --------
* Represents less than 1% of the shares of the Company's outstanding stock.
(1) According to Amendment No. 4 to the Schedule 13D Charles H. Robbins filed
on May 2, 1997. Includes 300,000 shares, or 2.6% of the class, owned by
Mr. Robbins' spouse, Ellen E. Robbins, individually and as trustee for
the benefit of their children. Also includes 790,000 which Mr. Robbins
presently could acquire upon the exercise of options granted by the
Company.
(2) The persons listed constitute a group within the meaning of Section
13(d)(3) of the Securities Exchange Act of 1934, as amended (the "1934
Act"), and jointly filed a Schedule 13D with the Securities and Exchange
Commission on October 11, 1994.
(3) Includes 200,000 shares owned by Shamrock Investments, 187,730 shares
owned by Mr. Reilly, 172,220 shares owned by Mr. Gallagher, 22,500 shares
which Shamrock Investments could acquire upon the exercise of options
granted by the Company, 231,596 shares which Mr. Reilly could acquire
upon the exercise of options granted by the Company, 121,262 shares which
Mr. Gallagher could acquire upon the exercise of options granted by the
Company, 59,963 shares which Mr. Reilly could acquire upon conversion of
a promissory note of the Company, 6,173 shares which Mr. Reilly could
acquire upon conversion of a promissory note of the Company issued to
Shamrock Investments, and 44,975 shares which Mr. Gallagher could acquire
upon conversion of a promissory note of the Company.
(4) According to the Schedule 13D filed on May 8, 1997, John W. Kluge is the
beneficial owner of these shares held by Chase Manhattan Bank, John W.
Kluge and Stuart Subotnick, trustees of a grantor trust of which John W.
Kluge is the beneficial owner.
(5) According to Amendment No. 1 to the Schedule 13D of Bosko Djordjevic and
Elizabeth Keck-Djordjevic, as trustee, filed on September 15, 1995.
(6) Includes 720,000 shares which Mr. Mazur could acquire upon the exercise
of options granted by the Company. Does not include either 512,014
shares, or 4.43% of the class, owned by VACHR, Inc., a corporation owned
by Mr. Mazur's spouse, Lynn Mazur, or 30,000 shares owned by J&J
Investment Partnership, a partnership wholly owned by members of Mr.
Mazur's family. Mr. Mazur disclaims beneficial ownership of the shares
owned by Lynn Mazur (through VACHR, Inc.) and J&J Investment Partnership.
(7) Includes 290,000 shares which Mr. Starr presently could acquire upon the
exercise of options granted by the Company.
4
<PAGE>
(8) Includes 53,333 shares which Mr. Bowles presently could acquire upon the
exercise of options granted by the Company.
(9) Represents the shares which Dr. Provato presently could acquire upon the
exercise of options granted by the Company.
(10) Represents the shares which Mr. Lubin presently could acquire upon the
exercise of options granted by the Company.
(11) Includes 1,000 shares which Dr. Schafer presently could acquire upon the
exercise of options granted by the Company.
PROPOSAL I: ELECTION OF DIRECTORS
ELECTION OF DIRECTORS
The Board is classified into three classes whose terms are staggered to
expire in different years. The term of office of one class of directors
expires each year in rotation so that one class is elected at each annual
meeting of shareholders for a full three-year term. The terms of four of the
present directors are expiring at the Annual Meeting. Directors elected at the
Annual Meeting will hold office for a three-year term expiring in 2000 or
until their successors are elected and qualified. Paul T. Cuzmanes and Dr.
George E. Schafer, whose terms expire at the Annual Meeting, are not standing
for re-election and will retire from the Board as of the Annual Meeting. John
J. McDonnell, whose term would otherwise expire at the 1988 annual meeting,
and Jerry W. Carlton, whose term would otherwise expire at the 1999 annual
meeting, have been nominated to stand for re-election to the board for terms
expiring at the annual meeting in 2000. The other six directors will continue
in office for the remainder of their terms as indicated below.
Proxies may not be voted for more than four nominees. The Board knows of no
reason why any nominee will be unavailable or unable to serve. If any nominee
should for any reason become unavailable for election, the proxy holders will
vote for such other nominee as may be proposed by the Board.
Certain information about the four nominees and other directors continuing
in office is set forth below, including any position(s) they hold with the
Company.
NOMINEES FOR ELECTION AS DIRECTORS FOR TERMS EXPIRING IN 2000
<TABLE>
<CAPTION>
POSITIONS OR OFFICES SERVED AS DIRECTOR
NAME WITH THE COMPANY CONTINUOUSLY SINCE AGE
---- -------------------- ------------------ ---
<S> <C> <C> <C>
Jerry W. Carlton........ None 1997 55
William J. Lubin........ Executive Vice President and 1997 45
Chief Executive Officer,
Commercial Managed Care
Division
John J. McDonnell....... None 1997 50
Charles P. Reilly....... None 1991 55
</TABLE>
Jerry W. Carlton was elected by the Board as a Director in June 1997. Mr.
Carlton is the Managing Partner of the Newport Beach, California office of the
law firm of O'Melveny & Myers L.L.P. and his specialties are tax and general
business law. He has handled hospital acquisitions and divestitures and has
been responsible for the legal aspects of provider relations for a large
managed care entity. In addition to serving on the Company's Board, Mr.
Carlton is a member of the boards of directors of Phoenix House, Prentice Day
School, Willametta K. Day Foundation, Arlington Investment Company, Vicente
Management Company and the Foley Timber Company.
William J. Lubin was elected by the Board as a Director in June 1997. Mr.
Lubin joined the Company in August 1994 as Senior Vice President for Managed
Care. In late 1994 he assumed the position of Chief Operating Officer,
Commercial Managed Care Division. In October 1995, he became Chief Executive
Officer,
5
<PAGE>
Commercial Managed Care Division. In April 1996, he became Executive Vice
President. Prior to joining the Company, Mr. Lubin held management positions
with Aetna Health Plans, Travelers Insurance Companies, Lincoln National and
Blue Cross and Blue Shield of Connecticut.
John J. McDonnell was elected by the Board as a Director in June 1997. Mr.
McDonnell is the co-founder, Chairman and CEO of Coagulation Diagnostics,
Inc., of Bethesda, Maryland. He also serves as the Secretary to the Board of
Directors and Counsel for Yurie Systems, Inc., a telecommunications firm. From
1990 to 1995, Mr. McDonnell was Counsel with Reed Smith Shaw & McClay, a law
firm. He also has held executive and legal positions with Fairchild Space and
Defense Corporation and Fairchild Industries, as well as with the Department
of the Navy. He is on the boards of directors of Sequoia National Bank and
several charitable and educational institutions.
Charles P. Reilly joined the Company as a Director in 1991 and became
Chairman of the Board in February 1997. Mr. Reilly is the managing general
partner of Shamrock Investments, a financial advisory and investment firm that
specializes in the health care industry. Mr. Reilly serves as Chairman of the
Board of Directors of Dynamic Health, Inc., an acute care hospital company,
and as a director of G & L Realty Corporation, a NYSE health care real estate
investment trust (REIT). Mr. Reilly has served as a director, trustee and
governing council member of the Federation of American Healthcare Systems and
The National Committee for Quality Health Care and the American Hospital
Association. From August 1994 to August 1995, Mr. Reilly was an officer of the
Company, serving as a member of the Executive Council.
DIRECTORS CONTINUING IN OFFICE IN THE CLASS OF 1998
<TABLE>
<CAPTION>
POSITIONS OR OFFICES SERVED AS DIRECTOR
NAME WITH THE COMPANY CONTINUOUSLY SINCE AGE
---- -------------------- ------------------ ---
<S> <C> <C> <C>
Jack M. Mazur........... President and Chief Executive 1976 55
Officer
Frank L. Provato, Executive Vice President and 1997 49
M.D. .................. Corporate Medical Director
Michael D. Starr........ Senior Executive Vice 1985 53
President, Treasurer, and Chief
Executive Officer, Government
Managed Care Division
</TABLE>
Jack M. Mazur has been a Director of the Company since 1976 and has served
as President since October 1995 and Chief Executive Officer since February
1997. Prior to his election as President, Mr. Mazur was Chief Executive
Officer of the Company's Commercial Managed Care Division. From August 1989 to
October 1995, he served as Senior Executive Vice President of the Company, and
from June 1986 to October 1993 as Secretary of the Company.
Frank L. Provato, M.D. was elected by the Board as a Director in June 1997.
Dr. Provato joined the Company in 1993 and currently serves as Executive Vice
President and Corporate Medical Director. Prior to joining the Company, he
served as Vice President and Corporate Medical Director for GTE Corporation,
where he was responsible for the development of health care cost management
strategies and the implementation of a GTE-sponsored primary care health
center in Tampa, Florida. Dr. Provato has 23 years of diverse background in
clinical medicine, health care administration, occupational health, and
employee benefits administration.
Michael D. Starr has been a Director since 1985. Mr. Starr was Executive
Vice President from 1986 to September 1995 and has served as Senior Executive
Vice President since October 1995. He has served as Chief Executive Officer,
Government Managed Care Division, since April 1995.
6
<PAGE>
DIRECTORS CONTINUING IN OFFICE IN THE CLASS OF 1999
<TABLE>
<CAPTION>
POSITIONS OR OFFICES SERVED AS DIRECTOR
NAME WITH THE COMPANY CONTINUOUSLY SINCE AGE
---- -------------------- ------------------ ---
<S> <C> <C> <C>
Robert L. Bowles, Jr. .. President, D.C. Chartered 1996 57
Health Plan, Inc.
Joseph G. Mathews....... None 1993 63
Donald J. Ruffing....... None 1991 76
</TABLE>
Robert L. Bowles, Jr. was elected by the Board as a Director in September
1996. Mr. Bowles joined the Company in connection with the Company's
acquisition of D.C. Chartered Health Plan, Inc. Mr. Bowles is the founder of
D.C. Chartered and has more than 30 years' experience in administration and
management of health care services and operations for corporations and the
military.
Joseph G. Mathews joined the Company as a Director in July 1993. Mr. Mathews
owns and operates Joseph G. Mathews & Associates, an insurance brokerage firm.
Mr. Mathews' professional designations include Chartered Financial Consultant
and Master of Science Financial Services. In addition to serving on the
Company's Board, Mr. Mathews is a member of the boards of directors of Lake of
the Ozarks General Hospital, Mark Twain Bank, Sanford Brown College,
Lindenwood College and Learfield Communication.
Donald J. Ruffing joined the Company as a Director in 1991. Colonel Ruffing
retired as the Chief of the Air Force Medical Service Corps, Office of the
Surgeon General, where he was responsible for developing plans, policies and
procedures for the management of the Air Force Medical Service Corps. In 1990,
Colonel Ruffing served as a team member of the Peer and Application Reviews,
Refugee Mental Health Programs for the National Institute of Mental Health.
DIRECTORS WHOSE TERMS EXPIRE AT THE ANNUAL MEETING
<TABLE>
<CAPTION>
POSITIONS OR OFFICES SERVED AS DIRECTOR
NAME WITH THE COMPANY CONTINUOUSLY SINCE AGE
---- -------------------- ------------------ ---
<S> <C> <C> <C>
Paul T. Cuzmanes........ None 1989 52
George E. Schafer, Senior Vice President for 1981 75
M.D. .................. Medical Affairs
</TABLE>
Paul T. Cuzmanes joined the Company as a Director in 1989. Mr. Cuzmanes is a
partner with the law firm of Wilson, Elser, Moskowitz, Edelman & Dicker. Mr.
Cuzmanes specializes in health care law, commercial law and the representation
of municipalities. He is a fellow in the American Society of Pharmaceutical
Law.
George E. Schafer, M.D., joined the Company as a Director in 1981. Dr.
Schafer serves as Senior Vice President for Medical Affairs and previously
served as Vice President/Medical Director. Dr. Schafer retired from the Air
Force with the rank of Lieutenant General, having served as Surgeon General of
the United States Air Force.
VOTE REQUIRED
The four nominees for election as directors at the 1997 Annual Meeting who
receive the greatest number of votes cast for the election of directors at
that meeting shall be elected directors, assuming there is a quorum present.
The aggregate number of votes entitled to be cast by all shareholders present
in person or represented by proxy at the meeting, whether those shareholders
vote "for," "against," or abstain from voting, will be counted for purposes of
determining the number of shares present for purposes of establishing a
quorum.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR EACH OF THE NOMINEES FOR
ELECTION AS DIRECTORS.
7
<PAGE>
BOARD OF DIRECTORS AND COMMITTEES
The Board held five meetings during the year ended April 30, 1997, and took
action by written consent in lieu of a meeting five times during such year.
Each of the incumbent directors attended at least 75% of the meetings of the
Board, and of the meetings of committees on which they serve, held while they
were on the Board and such committees in the year ended April 30, 1997.
The standing committees of the Board included the Audit Committee, the
Compensation Committee, and the Stock Option Committee during the 1997 fiscal
year. The Board has not appointed a nominating committee.
Messrs. Ruffing and Mathews were members of the Audit Committee for the
fiscal year ended April 30, 1997 and Mr. Cuzmanes was a member until November
25, 1996. The functions of the Audit Committee are to review the adequacy of
systems and procedures for preparing the financial statements of the Company
as well as the suitability of internal financial controls, and to review and
approve the scope and performance of the independent auditors' work. The Audit
Committee met once during the fiscal year ended April 30, 1997.
Messrs. Ruffing and Mathews were members of the Stock Option Committee for
the fiscal year ended April 30, 1997 and Mr. Cuzmanes was a member until
November 25, 1996. The functions of the Stock Option Committee are to
determine the amount and allocation of options to be granted under the
Company's 1986 Stock Option Plan and the Company's 1996 Incentive Plan. The
Stock Option Committee met twice during the fiscal year ended April 30, 1997,
and took action by written consent in lieu of a meeting fifteen times during
such year.
Messrs. Cuzmanes, Reilly and Mathews were members of the Compensation
Committee for the fiscal year ended April 30, 1997. The function of the
Compensation Committee is to recommend salary levels for the executive
officers of the Company. The Compensation Committee met once during the fiscal
year ended April 30, 1997.
In June 1997, the Stock Option Committee and the Compensation Committee were
combined into a single committee which is termed the Compensation Committee.
The reconstituted Compensation Committee is authorized to act as to such
matters as its two predecessor committees had authority, including reviewing
and determining executive officer compensation, awards and perquisites, and
administering the Company's 1986 Stock Option Plan and the Company's 1996
Incentive Plan. Messrs. Jerry W. Carlton, John J. McDonnell and Donald J.
Ruffing are members of the Compensation Committee.
EXECUTIVE COMPENSATION
EXECUTIVE OFFICERS
The following table sets forth certain information with respect to the
Company's executive officers. Each of the officers listed has been appointed
by, and serves at the discretion of the Board.
<TABLE>
<CAPTION>
CONTINUOUSLY SERVED
POSITIONS OR OFFICES AS EXECUTIVE OFFICER
NAME WITH THE COMPANY SINCE AGE
---- -------------------- -------------------- ---
<S> <C> <C> <C>
Jack M. Mazur........... President and Chief Executive 1976 55
Officer
Michael D. Starr........ Senior Executive Vice 1981 53
President, Treasurer, and Chief
Executive Officer, Government
Managed Care Division
Anthony M. Picini....... Executive Vice President and 1990 42
Chief Financial Officer
Robert L. Bowles, Jr.... President, D.C. Chartered 1997 57
Health Plan
</TABLE>
8
<PAGE>
<TABLE>
<CAPTION>
POSITIONS OR OFFICES AS EXECUTIVE OFFICER
NAME WITH THE COMPANY SINCE AGE
---- -------------------- -------------------- ---
<S> <C> <C> <C>
William J. Lubin........ Executive Vice President and 1994 45
Chief Executive Officer,
Commercial Managed Care
Division
Frank L. Provato, Executive Vice President and 1997 49
M.D. .................. Corporate Medical Director
Former Executive
Officers:
Charles H. Robbins...... Chairman of the Board and Chief 1976-1997 67
Executive Officer
John P. Cole............ Executive Vice President 1994-1996 56
</TABLE>
Anthony M. Picini has been with the Company since 1989. Previously, Mr.
Picini was with the accounting firm of KPMG Peat Marwick LLP, where he managed
the auditing and accounting of both public and private companies.
Charles H. Robbins founded the Company in 1976 and served as Chairman of the
Board and Chief Executive Officer of the Company until January 31, 1997. He
also served as President of the Company from its inception through October
1995.
John P. Cole served as Executive Vice President of the Company with
responsibility for marketing the Company's managed health care products and
services until December 31, 1996. Previously, he was President and Chief
Executive Officer of JP Cole & Associates which exclusively marketed PHP
products. JP Cole & Associates was merged into the Company in October 1994.
Mr. Cole is a 30-year veteran of the employee benefits field having held
senior executive positions with Prudential, AMI, Blue Cross of California and
Lincoln National Corporation. Prior to starting JP Cole & Associates in 1993,
Mr. Cole was Senior Vice President at Aetna Health Plans where he had
responsibility for both sales and delivery of health care in markets across
the United States.
For a summary of the business experience of each of the other executive
officers of the Company, see "Nominees for Election as Directors" and
"Directors Continuing in Office" above.
There are no family relationships among any of the directors and executive
officers.
9
<PAGE>
SUMMARY COMPENSATION
The following table sets forth certain information for each of the last
three fiscal years with respect to the compensation awarded to, earned by, or
paid to (i) all individuals serving as the Company's chief executive officer
during the fiscal year ended April 30, 1997, (ii) the next four most highly
compensated executive officers who were serving as executive officers at April
30, 1997 and (iii) up to two individuals who would have been among the four
most highly compensated executive officers but for the fact that such
individual was not serving as an executive officer of the Company at April 30,
1997.
<TABLE>
<CAPTION>
LONG TERM
COMPENSATION
------------
ANNUAL COMPENSATION AWARDS
------------------------------------ ------------
(A) (E) (G)
NAME AND OTHER ANNUAL (F) ALL OTHER
PRINCIPAL COMPENSATION OPTIONS/SARS COMPENSATION
POSITION YEAR SALARY ($) BONUS ($) ($) AWARD(S) ($)
--------- ---- ---------- --------- ------------ ------------ ------------
<S> <C> <C> <C> <C> <C> <C>
Jack M. Mazur,......... 1997 583,000 -0- (1) -0- 10,285(2)
President and Chief 1996 550,000 -0- -0- 17,636
Executive Officer 1995 400,000 66,667 720,000 21,688
Michael D. Starr,...... 1997 350,000 -0- (1) -0- 2,286(3)
Senior Executive Vice
President 1996 330,000 -0- -0- 9,362
1995 275,000 -0- 290,000 9,688
Robert L. Bowles,
Jr., ................. 1997 317,000 -0- (1) 10,000 88,948(4)
President, D.C. 1996 284,000 -0- -0- 82,473
Chartered Health Plan,
Inc. 1995 200,000 -0- 50,000 73,724
Frank L. Provato,...... 1997 281,000 -0- (1) 10,000 1,079(5)
Executive Vice
President 1996 250,000 -0- 27,500 581
1995 250,000 -0- 60,000 899
William J. Lubin,...... 1997 274,000 -0- (1) 10,000 632(6)
Executive Vice
President 1996 207,692 -0- 15,000 706
1995 154,800 -0- 100,000 620
FORMER EXECUTIVE OFFI-
CERS:
Charles H. Robbins,.... 1997 503,000 -0- (1) -0- 2,289,312(8)
Former Chairman 1996 625,000 -0- -0- 19,413
and Chief Executive
Officer(7) 1995 500,000 83,333 790,000 23,827
John P. Cole,.......... 1997 313,000 -0- (1) -0- 2,790(12)
Executive Vice
President(9) 1996 330,000 -0- -- -0- 1,636
1995 176,346(10) -0- 30,000(5) 1,488
</TABLE>
- --------
(1) Each of the named executive officers receives certain perquisites,
including the use of Company automobiles; such perquisites, however, do
not exceed the lesser of $50,000 or 10% of such officer's salary and
bonus.
(2) Includes $1,785 term life insurance premiums, $500 in 401(k) Plan
matching fees and $8,000 director's fees from D.C. Chartered Health Plan,
Inc.
(3) Includes $1,786 term life insurance premiums and $500 in 401(k) Plan
matching fees.
(4) Includes $3,954 term life insurance premiums, $500 in 401(k) Plan
matching fees, $8,000 director's fees from D.C. Chartered Health Plan,
Inc. and $76,494 forgiveness of debt related to the acquisition of D.C.
Chartered Health Plan, Inc.
(5) Includes $1,079 term life insurance premiums.
(6) Includes $632 term life insurance premiums.
(7) Mr. Robbins retired as Chairman and Chief Executive Officer as of January
31, 1997.
10
<PAGE>
(8) Includes $7,812 term life insurance premiums, $500 in 401(k) Plan
matching fees, $6,000 director's fees from D.C. Chartered Health Plan,
Inc., $2,000,000 retirement payment and $275,000 related to a one-year
noncompetition agreement.
(9) Mr. Cole served as Executive Vice President until December 31, 1996.
(10) Salary shown is that from Mr. Cole's date of employment, September 29,
1994, through the end of the fiscal year.
(11) Does not include options for 100,000 shares received by Mr. Cole upon the
merger of JP Cole & Associates into the Company in October 1994.
(12) Includes $2,790 term life insurance premiums.
OPTION GRANTS
The following table sets forth certain information regarding options granted
during fiscal 1997 by the Company to the individuals named in the Summary
Compensation Table.
<TABLE>
<CAPTION>
POTENTIAL REALIZABLE
VALUE AT ASSUMED
ANNUAL RATES
OF STOCK PRICE
APPRECIATION
INDIVIDUAL GRANTS FOR OPTION TERM
- ------------------------------------------------------------------------------ ---------------------
NO. OF % OF TOTAL
SECURITIES OPTIONS
UNDERLYING GRANTED TO MARKET
OPTIONS EMPLOYEES EXERCISE PRICE EXPIRATION
NAME GRANTED IN 1997 PRICE GRANT DATE DATE 5% 10%
---- ---------- ---------- -------- ---------- ---------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C> <C>
Jack M. Mazur........... -- -- -- -- -- -- --
Michael D. Starr........ -- -- -- -- -- -- --
Robert L. Bowles, Jr. .. 10,000 2.63% $23.50 $23.50 8/21/06 $ 147,790 $ 374,529
Frank L. Provato........ 10,000 2.63% $23.50 $23.50 8/21/06 $ 147,790 $ 374,529
William J. Lubin........ 10,000 2.63% $23.50 $23.50 8/21/06 $ 147,790 $ 374.529
Charles H. Robbins...... -- -- -- -- -- -- --
John P. Cole............ -- -- -- -- -- -- --
</TABLE>
OPTION EXERCISES
The following table sets forth certain information relating to stock options
exercised by and the number and value of unexercised options previously
granted to, the individuals named in the Summary Compensation Table during
fiscal 1997.
AGGREGATED OPTIONS/SAR EXERCISES IN FISCAL YEAR 1997
AND FY-END OPTION/SAR VALUES
<TABLE>
<CAPTION>
(D) (E)
NUMBER OF VALUE OF UNEXERCISED
UNEXERCISED IN-THE-MONEY
OPTIONS/SARS OPTIONS/SARS
(B) (C) AT 4/30/97 AT 4/30/97
(A) SHARES ACQUIRED VALUE EXERCISABLE/ EXERCISABLE/
NAME ON EXERCISE (#) REALIZED ($) UNEXERCISABLE UNEXERCISABLE
---- --------------- ------------ --------------- ---------------------
<S> <C> <C> <C> <C>
Jack M. Mazur........... -0- -0- 480,000/240,000 $4,836,666/$2,418,334
Michael D. Starr........ -0- -0- 193,333/96,667 $ 1,906,747/$953,378
Robert L. Bowles, Jr.... -0- -0- 33,333/26,667 $ 285,414/$142,711
Frank L. Provato........ -0- -0- 69,167/48,333 $ 585,835/$217,916
William J. Lubin........ -0- -0- 71,667/53,333 $ 599,129/$299,559
Charles H. Robbins...... -0- -0- 526,667/263,333 $5,290,253/$2,645,122
John P. Cole............ -0- -0- 130,000/0 $ 1,235,000/$0
</TABLE>
- --------
11
<PAGE>
401(K) PLAN
The Company established the PHP Healthcare Corporation 401(k) Plan (the
"401(k) Plan") effective January 1, 1991, pursuant to which employees may
defer compensation for income tax purposes under Section 401(k) of the
Internal Revenue Code of 1986, as amended (the "Code"). Participant
contributions will be invested at all times in any or all of six funds at the
direction of the participant. Participant contributions will be matched up to
$500 annually by the Company. The Company contributed $500 to the 401(k) Plan
during fiscal year 1997 on behalf of each of the participating named executive
officers.
DIRECTOR COMPENSATION
Employee directors do not receive additional compensation for serving on the
Board. The non-employee Chairman of the Board is paid $62,500 per quarter for
his service as Chairman. Other non-employee directors are paid $4,500 per
quarter for their services as directors, plus $650 for each special meeting of
the Board. In addition, each outside director serving on a particular
committee is paid $1,200 for attending up to three committee meetings annually
and $500 for each additional committee meeting. Each director is reimbursed
for travel expenses relating to attending meetings of the Board and its
committees.
The Company has adopted a Directors' Retainer Plan. For any fiscal quarter,
each director of the Company may elect to have the full amount of his retainer
paid in the form of Common Stock. The number of shares issued is calculated
based on the then current market value of the stock.
Under the Company's 1996 Incentive Plan, on an annual basis, each non-
employee director is granted 5,000 stock options at a purchase price equal to
the fair market value of a share of Common Stock on the grant date. Each such
option vests after three years if the optionee remains a Director on the third
anniversary of the grant.
EMPLOYMENT AGREEMENTS
The Company has entered into Employment Agreements with Jack M. Mazur and
Michael D. Starr. Under these agreements, Mr. Mazur is employed as President
and Chief Executive Officer and Mr. Starr is employed as Senior Executive Vice
President and Chief Executive Officer, Government Managed Care Division. The
agreements renew automatically on May 1 of each year unless terminated by
either the executive or the Company on ninety (90) days advance notice, or
otherwise in accordance with the agreements, except that no notice may be
given by the Company sooner than three years after a change in control (as
defined in the agreements). The agreements are currently in effect through
April 30, 1998. In the event of termination because of the executive's death
or disability, the Company will pay the executive or his estate a lump sum
severance payment equal to one year's salary and a pro rata bonus for the year
in which the termination occurs. In the event the Company terminates the
agreement other than for cause, death or disability or the executive
terminates the agreement because of certain adverse changes following a change
in control of the Company, then (a) the Company must pay the executive a lump
sum amount equal to three times the sum of the executive's base salary and
bonus; (b) the executive is entitled, for a period of three years, to
continuation of coverage at the Company's expense of the executive's
disability, medical and dental benefits; and (c) all restrictions on any
outstanding awards granted to the executive will lapse and be immediately
vested, all stock options will become fully exercisable and the executive will
have the right to require the company to purchase for cash any shares of
unrestricted stock and stock purchased upon the exercise of any options.
The Company has entered into an agreement with William J. Lubin under which,
if Mr. Lubin's employment is involuntarily terminated, he will be entitled to
receive continued compensation as a consultant for 18 months or until he
secures full time employment. Mr. Lubin serves as Executive Vice President and
Chief Executive Officer, Commercial Managed Care Division. Under the
agreement, if the Company is sold or acquired by way of merger, stock swap or
cash transaction whereby there is a change in control of at least 20% of the
voting power of the Company's outstanding shares, and if Mr. Lubin's
responsibilities and compensation are reduced, then Mr. Lubin's employment
will be deemed to have been involuntarily terminated.
12
<PAGE>
The Company has entered into an employment agreement with John P. Cole as of
December 27, 1996. Under this agreement, Mr. Cole is employed as a
nonexecutive employee of the Company with an annual salary of $240,000. The
agreement provides that if the Company is sold, merged or reorganized whereby
there is a change in control of more than 25% of the Company's outstanding
shares, a new Board of Directors is elected and existing management is
replaced, and if Mr. Cole's responsibilities and compensation are reduced, Mr.
Cole's employment will be deemed to have been involuntarily terminated
"without cause" and he will be entitled to receive continued compensation
throughout the remaining term of the agreement or any extension thereof. The
agreement is currently in effect through December 31, 1997.
RETIREMENT OF FORMER CHAIRMAN
Charles H. Robbins retired as Chairman and Chief Executive Officer of the
Company as of January 31, 1997. The Company provided Mr. Robbins a retirement
agreement that included a one-time payment of $2 million and a payment of
$275,000 related to a one-year noncompetition agreement. In connection with
the agreement, on May 2, 1997, Mr. Robbins repaid all outstanding notes
receivable and accrued interest due the Company under the Senior Executive
Loan Program and notes receivable related to certain life insurance policies.
The agreement contains additional clauses which include, among other things,
(i) a provision requiring that until the earlier of January 31, 1999 or a
Change of Control (as defined in the agreement), Mr. Robbins shall vote his
shares of Common Stock, at his option, (x) in accordance with the
recommendation of the Board or (y) pro rata in the same manner and proportion
that votes of the stockholders of the Company have been cast and (ii) a
provision restricting Mr. Robbins' disposition of Common Stock prior to
November 1, 1997 to 400,000 shares, of which 300,000 shares were sold as of
May 2, 1997 to a trust under which John W. Kluge is the grantor.
JOINT COMPENSATION AND STOCK OPTION COMMITTEE REPORT
The Compensation Committee and the Stock Option Committee are comprised of
non-employee members of the Board of Directors. The Compensation Committee is
responsible for setting and administering executive officer compensation
policies and programs. The Stock Option Committee is responsible for
determining the recipients and number of options, the timing of grants and the
option exercise prices, all in accordance with the terms of the Company's
Stock Option Plan. The Stock Option Committee considers the recommendations of
management and of the Compensation Committee.
The Company's executive compensation program is designed (i) to align
executive compensation closely with the Company's performance and shareholder
returns through equity-based incentives, (ii) to attract and retain the key
executives critical to the success of the Company and (iii) to motivate and
reward such individuals based on corporate and individual performance. In
developing compensation plans and setting compensation levels, the
Compensation Committee takes into consideration compensation programs offered
by other companies with which the Company competes for executives.
The components of the Company's executive compensation program for fiscal
year 1997 were (i) annual compensation consisting of base salaries, (ii) long-
term incentives and (iii) other benefits. Executive compensation is determined
and administered by the Compensation Committee on the basis of total
compensation rather than as separate free-standing components.
BASE SALARY
The Compensation Committee reviews each executive officer's base salary on
an annual basis. When reviewing the base salary, the Compensation Committee
takes into account the overall performance of the Company and the executive,
the competitive market for base salaries, the executive's responsibilities and
increases in the cost of living. In determining base salary compensation for
fiscal year 1997, the Compensation Committee considered financial and
operational results of the fiscal year and the contribution of the executive
officers to achieve those results, and the compensation packages for
executives of comparable position and responsibility in the industry.
13
<PAGE>
To provide additional incentive to achieve outstanding performance, the
Compensation Committee also makes cash bonuses to eligible executives based on
corporate and individual performance. The Compensation Committee believes the
cash bonus awards enhance the link between pay and performance and motivate
participants by clearly communicating to them the potential rewards for
corporate performance.
For fiscal year 1997, the Compensation Committee determined that, in light
of the earlier grant of stock options and the significant appreciation in the
Company's stock price, it was not necessary or appropriate to award cash bonus
to reward executives for performance. However, the Compensation Committee has
approved a 6% increase in the annual salary of the executives for fiscal 1998.
LONG-TERM INCENTIVES
The Compensation Committee believes that the financial interests of
executive officers should be aligned closely with those of shareholders
through stock ownership. Under the Amended and Restated 1986 Stock Option Plan
(the "1986 Plan"), the Compensation Committee approves the grant of stock
options to its key employees and officers after evaluating the contribution of
the executives to the Company's long-term performance and the importance of
their responsibilities within the Company. Stock options granted under the
1986 Plan generally have a term of ten years, vest over three to four years
and have an exercise price equal to the fair market value of the Common Stock
on the grant date. Each year, the Stock Option Committee reviews the
desirability of granting stock options under the 1986 Plan. In fiscal year
1997, the Company granted 380,084 stock options to executive officers and
other eligible employees to acquire shares of Common Stock at exercise prices
per share ranging from $11.63 to $35.00.
Under the Company's 1996 Plan (the "1996 Plan"), the Stock Option Committee
approves the grant of stock options, stock appreciation and dividend
equivalent rights, restricted stock, performance units and performance shares
(collectively, the "Awards") to its key employees, officers, employee
directors, consultants and advisors of the Company after evaluating their
contribution to the Company's long-term performance and importance of their
responsibilities to the Company. In addition, the 1996 Plan provides for the
non-discretionary grant of stock options to non-employee directors of the
Company upon election or appointment and annually thereafter. Each year, the
Stock Option Committee reviews the desirability of granting the awards. In
fiscal year 1997, no Awards except those granted to non-employee directors of
the Company were made.
DEDUCTIBILITY OF EXECUTIVE COMPENSATION
Section 162(m) of the Internal Revenue Code of 1986 (the "Code") generally
disallows a federal income tax deduction to any publicly held corporation for
compensation paid in excess of $1 million in any taxable year to the chief
executive officer or any of the four most highly compensated other executive
officers employed by the corporation on the last day of the taxable year.
Exceptions are made for, among other things, qualified "performance-based
compensation." Qualified performance-based compensation means compensation
paid solely on account of the attainment of objective performance goals,
provided that (i) performance goals are established by a compensation
committee consisting solely of two or more outside directors, (ii) the
material terms of the performance-based compensation are disclosed to and
approved by stockholders in a separate stockholder vote prior to payment and
(iii) prior to payment, the compensation committee certifies that the
performance goals were attained and other material terms were satisfied.
The Compensation Committee intends to structure its executive awards under
the 1996 Plan to take advantage of this Section 162(m) exception. In addition,
it is possible, but not intended at this date, that the Compensation Committee
may wish to award non-deductible compensation in other circumstances as they
deem appropriate. Moreover, in light of the ambiguities and uncertainties
under Section 162(m), no assurance can be given that compensation intended by
the Company to satisfy the requirements for deductibility under Section 162(m)
does in fact do so.
14
<PAGE>
CHIEF EXECUTIVE OFFICER COMPENSATION
During fiscal 1997, the Company's most highly compensated executive officer
was Jack M. Mazur, the Company's President and Chief Executive Officer. Mr.
Mazur participated in the Company's regular executive compensation programs.
The Compensation Committee's approach to determining Mr. Mazur's compensation
is to take into account the Company's financial and operational performance
(including its financial and operational goals for the fiscal year), the
Company's other corporate objectives (such as transitioning to a commercial
market-based managed health care company), comparable public company
compensation programs and his length of service. During this fiscal year, the
Compensation Committee re-evaluated Mr. Mazur's compensation with the
concurrence of the Board of Directors. Mr. Mazur did not receive any grants of
options for fiscal year 1997 under the 1986 Plan and the 1996 Plan.
Charles H. Robbins served as the Company's Chairman and Chief Executive
Officer until January 31, 1997. Mr. Robbins participated in the Company's
regular executive compensation programs. The Compensation Committee's approach
to determining Mr. Robbins' compensation had to take into account the
Company's financial and operational performance (including its financial and
operational goals for the fiscal year), the Company's other corporate
objectives (such as transitioning to a commercial market-based managed health
care company), comparable public company compensation programs and his length
of service. During this fiscal year, the Compensation Committee re-evaluated
Mr. Robbins' compensation with the concurrence of the Board of Directors. Mr.
Robbins did not receive any grants of options for fiscal year 1997 under the
1986 Plan and the 1996 Plan.
OTHER BENEFITS
The Compensation Committee retained the other elements of the current
executive compensation package (health and life insurance, use of Company
automobiles and, for the senior executive officers, split dollar life
insurance) for fiscal year 1997.
COMPENSATION COMMITTEE STOCK OPTION COMMITTEE
Charles P. Reilly Paul T. Cuzmanes
Joseph G. Mathews Donald J. Ruffing
Paul T. Cuzmanes Joseph G. Mathews
15
<PAGE>
STOCK PRICE PERFORMANCE GRAPH
The line graph below compares yearly percentage change in the cumulative
total shareholder return on the Company's Common Stock against the cumulative
total return on the Standard and Poor's 500 Stock Index and the Standard and
Poor's Healthcare Sector for the period of five years commencing on April 30,
1992.
COMPARISON OF FIVE YEAR CUMULATIVE TOTAL RETURN*
Among PHP Healthcare Corporation, the S&P 500 Index
And the S&P Healthcare Sector Index
[LINE GRAPH APPEARS HERE]
* $100 invested on 4/30/92 in stock or index - including reinvestment of
dividends. Fiscal year ending April 30.
<TABLE>
<CAPTION>
CUMULATIVE TOTAL RETURN
-----------------------------
4/92 4/93 4/94 4/95 4/96 4/97
---- ---- ---- ---- ---- ----
<S> <C> <C> <C> <C> <C> <C> <C>
PHP Healthcare Corp. .................. PPH 100 42 60 110 349 160
S & P 500.............................. 1500 100 109 115 135 176 220
S & P Healthcare Sector................ IHCC 100 85 81 114 161 216
</TABLE>
16
<PAGE>
CERTAIN TRANSACTIONS AND BUSINESS RELATIONSHIPS
In September 1995, the Company retained Shamrock Investments ("Shamrock") as
a financial advisor. Charles P. Reilly, the managing general partner of
Shamrock, was a director of the Company and became Chairman of the Board in
February 1997. Michael E. Gallagher is a general partner of Shamrock. During
fiscal 1997, total billings approximated $233,000.
The Company has a Senior Executive Loan Program (the "Program"), pursuant to
which loans to senior executive officers may be made up to three and one-half
times the officer's annual salary. Each loan must be repaid within one year
and bears interest at two percent above the Company's short-term borrowing
rate. All loans are collateralized by the shares of the Company's Common Stock
owned by the senior executive officer. The due dates on amounts outstanding
were extended in 1997 for twelve months. During fiscal year 1997, loans were
outstanding under the Program to Charles H. Robbins, Jack M. Mazur, Michael D.
Starr and William J. Lubin. The largest amount outstanding during fiscal 1997
to Mr. Robbins was $1,596,000, to Mr. Mazur was $2,128,000, to Mr. Starr was
$800,000 and to Mr. Lubin was $48,000. The interest rate on these loans as of
July 1997 was 10.5%. The loan to Mr. Robbins was repaid May 2, 1997.
The Company advanced amounts to Robert L. Bowles, Jr. in the form of
promissory notes bearing interest at 8.5% collateralized by Mr. Bowles' stock
in the Company. The largest amount outstanding during fiscal 1997 was
$767,000.
In accordance with the Board of Directors' approval, the Company makes
premium payments relating to certain insurance policies on behalf of certain
officers of the Company. These advances are owed to the Company and are
collateralized by assignment of the underlying cash surrender value and
related death benefit. During 1995, the officers signed promissory notes
bearing interest at 7% and due in April 2002 for the amounts advanced. The
amount outstanding as of April 30, 1997, to Mr. Robbins was $745,000, to Mr.
Mazur was $231,000, to Mr. Starr was $207,000 and to Mr. Lubin was $20,000.
The note from Mr. Robbins was repaid May 2, 1997.
Paul Cuzmanes is a partner with the law firm of Wilson, Elser, Moskowitz,
Edelman & Dicker, which firm the Company retained in fiscal 1997. During the
year ended April 30, 1997, total billings approximated $321,000.
The Company also provided Charles B. Robbins, Ellen Robbins (individually
and as trustee under trusts for the benefit of two of their children, Caroline
H. Robbins and Lee S. Robbins) and Charles B. Robbins, with certain
registration rights for the Common Stock they beneficially owned as of
February 24, 1997, subject to certain restrictions on the timing of
dispositions contained in Mr. Robbins' Employment Agreement, and the Common
Stock under Company options held by Charles B. Robbins.
Joseph G. Mathews is the owner of an insurance brokerage firm through which
the Company purchased keyman life insurance policies covering certain
executive officers from various insurance companies. During fiscal 1997,
premiums by those insurance companies to Mr. Mathews' firm approximated
$443,000.
For further information with respect to related party transactions, see Note
12 of Notes to Consolidated Financial Statements.
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the 1934 Act requires the Company's executive officers and
directors, and persons who own more than ten percent of a registered class of
the Company's equity securities, to file reports of ownership and changes in
ownership on Forms 3, 4 and 5 with the Securities and Exchange Commission
("SEC") and the New York Stock Exchange. Executive officers, directors and
greater than ten percent shareholders are required by the SEC regulation to
furnish the Company with copies of all Forms 3, 4 and 5 they file.
17
<PAGE>
Based on the Company's review of the copies of such forms it has received
and based on written representations from certain reporting persons that they
were not required to file Forms 5 for the fiscal year, except as noted below,
the Company believes that all its executive officers, directors and greater
than ten percent shareholders complied with all filing requirements applicable
to them with respect to transactions during fiscal 1997. Certain of the
Company's directors failed to report on a timely basis certain option grants
under the Company's 1996 Incentive Plan, as follows: Charles P. Reilly, Paul
T. Cuzmanes, Donald J. Ruffing and Joseph G. Mathews (each one late report
with respect to one transaction). These transactions were reported on Forms 5
filed in September 1997.
PROPOSAL II: AMENDMENT TO CERTIFICATE OF INCORPORATION TO INCREASE CAPITAL
STOCK
The Board has approved and declared the advisability of an amendment to
Article 4 (the "Amended Article 4") of the Company's Restated Certificate of
Incorporation, as currently in effect (the "Certificate"), (i) to increase the
number of authorized shares of the Company's Common Stock from 25,000,000
shares to 100,000,000 shares, (ii) to increase the number of authorized shares
of the Company's Preferred Stock from 500,000 shares to 10,000,000 shares, and
(iii) to authorize the Board to provide for the issuance of shares of
Preferred Stock in one or more series, to establish the number of shares to be
included in each such series and to fix the designations, powers, preferences,
and rights of each such series, and any qualifications, limitations or
restrictions thereof. A copy of the Amended Article 4 is attached hereto as
Annex A.
As of the Record Date, 11,559,930 shares of the Company's Common Stock were
issued and outstanding, 3,155,740 shares were reserved for issuance upon the
exercise of options granted under the Amended and Restated PHP Healthcare
Corporation 1986 Stock Option Plan (the "1986 Plan"), 132,000 shares were
reserved for issuance upon the exercise of options granted under the PHP
Healthcare Corporation 1996 Incentive Plan (the "1996 Plan"), 2,532,110 shares
were reserved for issuance upon the conversion of certain convertible
subordinated debentures of the Company due December 15, 2002, and 523,969
shares were reserved for issuance upon the exercise or conversion of other
outstanding options, warrants, convertible debentures and rights. As a result,
the Company had 7,096,251 shares of authorized but unissued Common Stock
(including shares held in treasury). In addition, 409,000 shares of Common
Stock are available for future grants under the 1986 Plan and the 1996 Plan,
and, if the amendment to the 1996 Plan as set forth in Proposal III is adopted
by the stockholders at the Annual Meeting, an additional 2,500,000 shares of
Common Stock will be available for future grants. As of the Record Date, no
shares of Preferred Stock were outstanding. 50,000 shares of the Company's
Preferred Stock were designated as Series A Junior Participating Preferred
Stock which were reserved for issuance under the Company's Shareholder Rights
Plan. A total of 450,000 authorized shares of Preferred Stock remain available
for subsequent issuance.
Like most companies, the Company has historically maintained a substantial
reserve of authorized but unissued shares in order to avoid the time and
expense of seeking shareholder approval each time it needs to make new
issuance of Common Stock and Preferred Stock in light of possible future
activities which the Board deems to be in the best interests of the
stockholders. The Board believes that the availability of such additional
shares would provide the Company with the flexibility to promptly consider and
respond to future business opportunities and needs as they arise. There are
presently no arrangements, understandings, agreements or plans to issue
additional shares of Common Stock or Preferred Stock to be authorized under
the Amended Article 4 (other than shares previously reserved for issuance as
described above).
In order to finance in part the previously announced acquisition by the
Company of certain assets from HIP of New Jersey, Inc., the Company may issue
additional debt or equity securities in a public or private offering. However,
the equity securities, if any, issued in connection with the HIP acquisition
will be issued out of the Company's existing authorized capital stock and will
not include the additional shares to be authorized under the Amended Article
4.
If the Amended Article 4 is adopted by the stockholders of the Company, the
additional shares of Common Stock and Preferred Stock would be issuable, at
any time from time to time, by action of the Board without further
authorization of the stockholders, except as provided under applicable laws.
The additional Common
18
<PAGE>
Stock to be authorized under the Amended Article 4 would have rights identical
to the currently outstanding Common Stock of the Company. Current holders of
Common Stock do not have statutory preemptive rights or other statutory rights
to subscribe for additional shares of Common Stock that may be issued in the
future. To the extent that additional shares of Common Stock are issued in the
future and existing stockholders do not participate to the extent of their
proportional interests, such issuance will decrease stockholders' percentage
equity ownership and, depending on the price at which such shares are issued,
could be dilutive to the existing shareholders.
The additional Preferred Stock authorized under the Amended Article 4 would
have rights, preferences and privileges designated by the Board from time to
time pursuant to the Amended Article 4. The voting and conversion rights
provided to such shares could adversely affect the voting power and beneficial
ownership interests of the holders of Common Stock.
The Certificate currently provides that Preferred Stock shall have voting
rights equal to those of Common Stock except to the extent the voting rights
of any series of Preferred Stock shall be denied or limited by the Board
authorizing by resolution. If the Amended Article 4 is approved, it would
remove such restrictions on the voting rights of the authorized but not
designated Preferred Stock (including the additional shares of Preferred Stock
authorized thereunder) and would authorize the Board to determine the voting
rights of Preferred Stock by resolution without any action by stockholders.
The Board believes that this amendment will provide the Board with the
capability to determine the terms of Preferred Stock according to the needs of
the Company and the flexibility to take advantage of future business
opportunities.
ANTI-TAKEOVER EFFECTS AND OTHER PROVISIONS
The proposed increase in the number of authorized shares of Common Stock and
Preferred Stock could have a potential anti-takeover effect. The availability
of additional shares of Common Stock and Preferred Stock will enable the
Company to discourage unsolicited takeover attempts or delay or prevent
changes in control of the management of the Company which the Board determines
are not in the best interests of the Company and its stockholders. For
example, if the Company were the subject of a hostile takeover attempt, it
could try to impede the takeover by issuing shares of Common Stock or
Preferred Stock, thereby diluting the voting power of the outstanding shares
and increasing the potential cost of the takeover. The Board currently is not
aware of any attempt or contemplated attempt to acquire control of the
Company.
In addition to the proposed amendments to the Certificate described above,
the existing provisions of the Certificate and the Company's Amended and
Restated Bylaws, Delaware law and the Company's Shareholder Rights Plan could
deter, to varying degrees and in varying circumstances, an effort to take
control of the Company. These provisions and the agreement are summarized
below. The summary is qualified in its entirety by reference to the particular
provisions and such agreement. While neither management nor the Board has any
current plans to adopt further anti-takeover provisions or agreements, they
may from time to time consider measures which have an anti-takeover effect and
may adopt or recommend their adoption if they believe the measures to be in
the best interests of the Company.
Shareholder Rights Plan. Under the Company's Shareholder Rights Plan, one
Right is presently attached to and trades with each outstanding share of the
Company's Common Stock. The Rights become exercisable after public
announcement that, without consent of a majority of disinterested members of
the Board, a third party has acquired or obtained beneficial ownership of 15%
or more of the outstanding Common Stock or 10 business days after commencement
or public announcement of an offer of such an event. Once exercisable, each
Right entitles the holder to purchase one one-thousandth (1/1000th) share of
Series A Preferred Stock at an exercise price of $45, subject to adjustment.
The Rights, which have no voting rights, expire in April 2002, and may be
redeemed in whole by the Company at $.01 per Right at any time prior to their
expiration or the acquisition by a third party of 15% or more the Company's
Common Stock. In the event that the Company is acquired in a merger or other
business combination transaction or 50% or more of its consolidated assets or
earning power is sold, provision shall be made so that each holder of a Right
shall have the right to receive,
19
<PAGE>
upon exercise thereof at the then current exercise price, that number of
shares of common stock of the surviving company which at the time of such
transaction would have a market value of two times the exercise price of the
Right.
Delaware Takeover Statute. In general, Section 203 of the Delaware General
Corporation Law restricts for three years certain business combination between
a Delaware corporation and a shareholder that acquires 15% or more of the
Company's voting stock. An exception is provided where the shareholder, in
crossing the 15% threshold, acquires more than 85% of the Company's total
voting shares (excluding shares held by directors who are also officers and by
certain employee benefit plans) in a single transaction. Business combinations
with 15% shareholders would be permitted where prior to the date the person
became a 15% holder, the Board approved either the business combination or the
transaction that resulted in the person becoming a 15% shareholder, or on or
after such date, the business combination was approved by the Board and
authorized at an annual or special meeting of shareholders by the affirmative
vote of at least two-thirds of the outstanding voting stock that is not owned
by the 15% shareholders or its affiliates and associates.
Classified Board. The Certificate classifies the Board into three classes of
directors serving staggered three-year terms.
Special Meetings of Shareholders. Pursuant to the Company's Amended and
Restated Bylaws, as currently in effect (the "Bylaws"), the stockholders of
the Company are not empowered to call a special meeting of the shareholders or
to require that such a meeting be called by the Board or the officers of the
Company. The Bylaws provide that special meetings of shareholders may only be
called by the Company's Chief Executive Officer and President and the Board.
Shareholder Nominations and New Business. The Bylaws require that
nominations made by a shareholder for the election of a director at any annual
meeting of shareholders include certain prescribed information and be
submitted in writing to the Secretary of the Company not less than ninety (90)
days prior to the anniversary date of the immediately preceding annual
meeting. The Bylaws also require that the new business items proposed by
shareholders at any annual meeting of shareholders be submitted in accordance
with prescribed procedures and be received by the Secretary of the Company not
less than sixty days nor more than ninety days prior to the date of the annual
meeting.
Shareholder Actions. The Bylaws do not permit shareholders to take action
without a meeting.
Supermajority Vote for Amendment of the Bylaws. The Bylaws provide that the
Bylaws may be adopted, amended or repealed by the affirmative vote of the
holders of two-thirds of the stock of the Company issued and outstanding and
entitled to vote thereon.
Available Capital Stock. The Company has 450,000 shares of authorized but
unissued Preferred Stock (in addition to 50,000 unissued shares of Series A
Preferred Stock reserved for issuance under the Shareholder Rights Plan). The
Board has authority to fix the terms of Preferred Stock prior to its issuance.
Additionally, as of the Record Date, the Company had 10,182,251 shares of
unissued Common Stock (including the shares held in treasury). Such stock
could be used by the Board for defense purposes, including its issuance or
sale to third parties or use in recapitalization transactions.
VOTE REQUIRED
Approval of the Amended Article 4 requires the affirmative vote of the
holders of a majority of the outstanding shares of Common Stock entitled to
vote.
FOR THE REASONS STATED HEREIN, THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT STOCKHOLDERS VOTE FOR APPROVAL OF THE AMENDMENTS TO THE CERTIFICATE OF
INCORPORATION
20
<PAGE>
PROPOSAL III: AMENDMENTS TO PHP HEALTHCARE CORPORATION 1996 INCENTIVE PLAN
GENERAL
The Company's stockholders are being asked to approve the PHP Healthcare
Corporation Amended and Restated 1996 Incentive Plan (the "Amended Plan"). The
Board has adopted the Amended Plan, subject to stockholder approval, and
recommends that stockholders vote to approve the Amended Plan.
The PHP Healthcare Corporation 1996 Incentive Plan was originally adopted by
the Board in October 1996 and approved by the Company's stockholders in
November 1996.
The proposed amendments contained in the Amended Plan will (i) increase the
number of shares of Common Stock authorized for grant or award under the
current plan from 500,000 to 3,000,000, (ii) increase the maximum number of
shares with respect to which options or awards may be granted to any
individual during any calendar year from 150,000 to 500,000 and the maximum
dollar amount that any individual may receive in respect of cash-denominated
performance units per calendar year from 100% of such individual's aggregate
base salary to $2,500,000, (iii) add the maximum number of share with respect
to which options or awards may be granted to the Chief Executive Officer, and
the maximum dollar amount that the Chief Executive Officer may receive in
respect of cash-denominated performance units, per calendar year, and (iv) add
the effect of termination of employment caused by retirement on the options or
awards.
The principal provisions of the Amended Plan are summarized below. This
summary, however, does not purport to be complete and is qualified in its
entirety by reference to the provisions of the Amended Plan, a copy of which
is attached hereto as Annex B. Terms not defined herein shall have the
meanings set forth in the Amended Plan.
PURPOSE
The purpose of the Amended Plan is to strengthen the Company by providing an
incentive to its employees, officers, consultants and directors through the
granting or awarding of incentive and nonqualified stock options, stock
appreciation and dividend equivalent rights, restricted stock, performance
units, and performance shares to employees, officers, employee directors,
consultants and advisors and the granting of option to non-employee directors
of the Company (collectively or individually, "Awards"), thereby encouraging
them to devote their abilities and energies to the success of the Company.
ADMINISTRATION
The Amended Plan is to be administered by a committee consisting of at least
two directors of the Company (the "Committee"), and it may be administered by
the entire Board. If the Committee consists of less than the entire Board,
each member will be a "non-employee director" within the meaning of Rule 16b-3
promulgated under the 1934 Act. The extent necessary for any Award to qualify
as performance-based compensation under Section 162(m) of the Code, each
member of the Committee will be an "outside director" within the meaning of
Section 162(m) of the Code.
Each Award under the Amended Plan will be evidenced by an agreement that
sets forth the terms of the grant. Under the Amended Plan, the Committee has
the authority to, among other things: (i) select the employees to whom Awards
will be granted, (ii) determine the type, size and the terms and conditions of
Awards and (iii) establish the terms for treatment of Awards upon a
termination of employment.
SHARES AVAILABLE FOR ISSUANCE
Under the Amended Plan, 3,000,000 shares of authorized and unissued Common
Stock will be available for the grant of Awards to Eligible Individuals,
provided that the maximum number of shares with respect to which
21
<PAGE>
Awards may be granted to any individual (other than the Chief Executive
Officer) and the Chief Executive Officer over the term of the plan is 500,000
and 1,000,000, respectively, during any calendar year. In the event of any
Change in Capitalization (as defined in the Amended Plan), however, the
Committee may adjust the maximum number and class of shares with respect to
which Awards may be granted, the number and class of shares which are subject
to outstanding Awards and the purchase price thereof. Of the total number of
shares allotted under the Plan, not more than one-third of the number of
allotted shares may be used for restricted stock grants and the maximum dollar
amount that any individual (other than the Chief Executive Officer) and the
Chief Executive Officer may receive during any calendar year respect of cash-
denominated performance units may not exceed $2,500,000 and $10,000,000,
respectively.
STOCK OPTIONS
The Committee will determine whether any option is a non-qualified or
incentive stock option at the time of grant. The per share exercise price of
an option granted under the Amended Plan will be determined by the Committee
at the time of grant and set forth in the option agreement, provided that the
purchase price per share under each incentive stock option must not be less
than 100% of the fair market value of the Common Stock of the Company subject
to the option at the date of grant (110% in the case of an incentive stock
option granted to a "Ten Percent Stockholder" (as defined in the Amended
Plan)). Each option will be exercisable at such dates and in such installments
as determined by the Committee. Unless otherwise provided in the applicable
option agreement, all outstanding options will become fully exercisable upon a
"Change in Control" (as defined in the Amended Plan). In addition, the
Committee reserves the authority to accelerate the exercisability of any
option. Each option terminates at the time determined by the Committee
provided that the term of each option may not exceed ten years (five years in
the case of any incentive stock options granted to a Ten Percent Stockholder).
Unless otherwise determined by the Committee, options are not transferable
except by will or the laws of descent and distribution or pursuant to a
domestic relations order. Options may be exercised during the optionee's
lifetime only by the grantee or his guardian or legal representative. In the
discretion of the Committee, the purchase price for shares may be paid (i) in
cash, (ii) by transferring shares of Common Stock to the Company, or (iii) by
a combination of the foregoing. In addition, options may be exercised through
a registered broker-dealer pursuant to such cashless exercise procedures which
are, from time to time, deemed acceptable by the Committee.
If the fair market value of Common Stock exceeds the exercise price of an
option on the date of exercise, an optionee may request that the Committee
authorize payment to the optionee of the difference between the fair market
value of part or all of the shares subject to the option and the exercise
price of the option. The Committee in its sole discretion may grant or deny
such a request. To the extent granted, the Committee will direct the company
to make the payment to the optionee in cash, shares of Common Stock or in any
combination thereof. An option will be deemed to be exercised and canceled to
the extent that the Committee grants the request.
Unless otherwise provided in an optionee's employment agreement or option
agreement, if an optionee's employment is terminated by the Company for any
reason other than for "Cause" (as defined in the Amended Plan) or voluntarily
by the optionee prior to serving five years as an employee of the Company,
options which were exercisable as of the date of the termination will remain
exercisable until the earlier of (i) ninety days after the date of termination
or (ii) the expiration of the stated term of the option. Upon termination of
an optionee's employment by the Company for "Cause" or voluntarily by the
optionee prior to five years of service with the Company, unless determined
otherwise by the Committee, any unexercised options held by such optionee will
terminate and expire concurrently with the optionee's termination of
employment. Upon termination of an optionee's employment caused by his or her
"Disability" or "Retirement" (as defined in the Amended Plan), any unexercised
options held by such optionee will expire one year after the date of
termination subject to the expiration date of the option. Upon termination of
an optionee's employment caused by his or her death, options which were
exercisable as of the date of death will remain exercisable until the earlier
of (i) one year after the date of the optionee's death or (ii) the expiration
of the stated term of the option.
22
<PAGE>
DIRECTOR OPTIONS
The Amended Plan also provides for the non-discretionary grant of options to
each of its non-employee directors ("Director Options") (i) with respect to
5,000 shares of Common Stock of the Company to each non-employee director who
becomes a member of the Board after October 1, 1996, upon election or
appointment and (ii) with respect to 5,000 shares of Common Stock of the
Company annually on the first business day on or after October 24 of each
calendar year that the Amended Plan is in effect to all non-employee directors
who are members of the Board at that time; provided, however, that a director
shall not be entitled to receive an annual grant during the year in which such
director is appointed or elected. Director Options are granted at a purchase
price equal to the fair market value of Common Stock of the Company such to
such Director Options on the date of grant. Director Options vest with respect
to 100% of the shares subject to such Director Options on the third
anniversary of the date of grant; provided that the director remains in
service at the time. Director Options generally have ten-year terms, unless
earlier terminated in accordance with the provisions of the Amended Plan.
STOCK APPRECIATION RIGHTS ("SARS")
The Amended Plan permits the granting of SARs either in connection with the
grant of an option (other than a Director Option) or as a freestanding right.
A SAR permits a grantee to receive upon exercise of the SAR, cash and/or
shares, at the discretion of the Committee, in an amount equal in value to the
excess, if any, of the then per share fair market value over the per share
fair market value on the date the SAR was granted (or option exercise price in
the case of a SAR granted in connection with an option). When a SAR is
granted, however, the Committee may establish a limit on the maximum amount a
grantee may receive on exercise. The Committee will decide at the time the SAR
is granted the date or dates at which it will become vested and exercisable;
however, in the event of a Change in Control of the Company, all SARs become
immediately and fully exercisable.
DIVIDEND EQUIVALENT RIGHTS ("DERS")
DERs may be granted in tandem with any Award under the Amended Plan and may
be payable currently or deferred until the lapsing of the restrictions on the
DERs or until the vesting, exercise, payment, settlement or other lapse of
restrictions on the related Award. DERs may be settled in cash or shares of
Common Stock or a combination thereof, in a single or multiple installments.
RESTRICTED STOCK
The Committee will determine the terms of each restricted stock Award at the
time of grant, including the price, if any, to be paid by the grantee for the
restricted stock, the restrictions placed on the shares, and the time or times
when the restrictions will lapse. In addition, at the time of grant, the
Committee, in their discretion, may decide: (i) whether any deferred dividends
will be held for the account of the grantee or deferred until the restrictions
thereon lapse, (ii) whether any deferred dividends will be reinvested in
additional shares of Common Stock or held in cash, (iii) whether interest will
be accrued on any dividends not reinvested in additional shares of restricted
stock and (iv) whether any stock dividends paid will be subject to the
restrictions applicable to the restricted stock Award. Unless otherwise
provided at the time of grant, the restrictions on the restricted stock will
lapse upon a Change in Control.
PERFORMANCE UNITS AND PERFORMANCE SHARES
Performance units and performance shares will be awarded as the Committee
may determine, and the vesting of performance units and performance shares
will be based upon the Company's attainment within an established period of
specified performance objectives to be determined by the Committee among the
following: earnings per share, share price, pre-tax profits, net earnings,
return on equity or assets, revenues, EBITDA, market share or market
penetration or any combination of the foregoing. Each agreement evidencing the
Award of performance units will specify either a fixed number of performance
units to which it relates or a formula pursuant to which the number of
performance units may be calculated, the performance objectives which must
23
<PAGE>
be satisfied in order for the performance units to vest and the performance
cycle within which such performance objectives must be satisfied. Performance
units may be denominated in dollars or in shares of Common Stock, and payments
in respect of performance units will be made in cash, shares, shares of
restricted stock or any combination of the foregoing, as determined by the
Committee. In the event of a Change in Control, unless otherwise determined by
the Committee, all performance units will vest and all restrictions on
performance shares will lapse.
AMENDMENTS AND TERMINATION
The Amended Plan will terminate on the day preceding the twenty anniversary
of the date of its adoption by the Board of Directors. The Board of Directors
may at any time and from time to time amend or terminate the Amended Plan;
provided, however, that, to the extent necessary under applicable law, no such
change will be effective without the requisite approval of the Company's
stockholders. In addition, no such change may alter or adversely impair any
rights or obligations under any Awards previously granted, except with the
written consent of the grantee.
CERTAIN FEDERAL INCOME TAX CONSEQUENCES
The following discussion is generally a summary of the principal United
States federal income tax consequences under current federal income tax laws
relating to grants or awards to employees under the Amended Plan. The summary
is not intended to be exhaustive and, among other things, does not describe
state, local or foreign income and other tax consequences.
Stock Options
An optionee will not recognize any taxable income upon the grant of a non-
qualified option and the Company will not be entitled to a tax deduction with
respect to such grant. Generally, upon exercise of a non-qualified option, the
excess of the fair market value of Common Stock on the date of exercise over
the exercise price will be taxable as ordinary income to the optionee. If the
Company complies with applicable withholding requirements, the Company will be
entitled to a tax deduction in the same amount and at the same time as the
optionee recognizes ordinary income, subject to any deduction limitation under
Section 162(m) of the Code (which is discussed below). The subsequent
disposition of shares acquired upon the exercises of a nonqualified option
will ordinarily result in capital gain or loss.
Subject to the discussion below, an optionee will not recognize taxable
income at the time of grant or exercise of an "incentive stock option" and the
Company will not be entitled to a tax deduction with respect to such grant or
exercise. However, the exercise of an "incentive stock option" may result in
an alternative minimum tax liability for the optionee.
Generally, if an optionee has held shares acquired upon the exercise of an
"incentive stock option" for at least one year after the date of exercise and
for at least two years after the date of grant of the "incentive stock
option," upon disposition of the shares by the optionee, the difference, if
any, between the sales price of the shares and the exercise price will be
treated as long-term capital gain or loss to the optionee. Generally, upon a
sale or other disposition of shares acquired upon the exercise of an
"incentive stock option" within one year after the date of exercise or within
two years after the date of grant of the "incentive stock option" (a
"disqualifying disposition"), any excess of the fair market value of the
shares at the time of exercise of the option over the exercise price of such
option will constitute ordinary income to the optionee. Any excess of the
amount realized by the holder on the disqualifying disposition over the fair
market value of the shares on the date of exercise will generally be capital
gain. Such to any deduction limitation under Section 162(m) of the Code, the
Company will be entitled to a deduction equal to amount of such ordinary
income recognized by the holder.
24
<PAGE>
If an option is exercised through the use of shares previously owned by the
holder, such exercise generally will not be considered a taxable disposition
of the previously owned shares and thus no gain or loss will be recognized
with respect to such shares upon such exercise. However, if the option is an
"incentive stock option," and the previously owned shares were acquired on the
exercise of an "incentive stock option" and the holding period requirement for
those shares is not satisfied at the time they are used to exercise the
Option, such use will constitute a disqualifying disposition of the previously
owned shares resulting in the recognition of ordinary income in the amount
described above.
Special rules may apply in the case of an optionee who is subject to Section
16 of the 1934 Act.
Stock Appreciation Rights
The amount of any cash (or the fair market value of any shares) received
upon the exercise of a stock appreciation right under the Amended Plan will be
includible in the grantee's ordinary income and, subject to satisfying
applicable withholding requirements and any Company deduction limitation under
Section 162(m) of the Code.
Restricted Stock
A grantee will not recognize taxable income upon the grant of restricted
stock, and the recognition of any income will be postponed until such shares
are no longer subject to the restriction or the risk of forfeiture. When
either the restrictions or the risk of forfeiture lapses, the grantee will
recognize ordinary income equal to the fair market value of the restricted
stock at the time that such restrictions lapse and, subject to satisfying
applicable withholding requirements and deduction limitation under Section
162(m) of the Code, the Company will be entitled to a deduction. A grantee may
elect to be taxed at the time of the grant of restricted stock and, if this
election is made, the grantee will recognize ordinary income equal to the
excess of the fair market value of the restricted stock at the time of grant
determined without regard to any of the restrictions thereon over the amount
paid, if any, by the grantee for such shares.
Performance Shares and Performance Units
Generally, a grantee will not recognize any taxable income and the Company
will not be entitled to a deduction upon the award of performance share or
performance units. At the time the grantee receives the distribution in
respect to the performance shares or the performance units, the fair market
value of shares or the amount of any cash received in payment for such Awards
generally is taxable to the grantee as ordinary income and, subject to the
Company deduction limitation under Section 162(m) of the Code.
Dividend Equivalents
A grantee realizes ordinary income upon the receipt of dividend equivalents
in an amount equal to any cash received.
Section 162(m)
Section 162(m) of the Code generally disallows a federal income tax
deduction to any publicly held corporation for compensation paid in excess of
$1 million in any taxable year to the chief executive officer or any of the
four other most highly compensated executive officers who are employed by the
corporation on the last day of the taxable year, but does allow a deduction
for "performance-based compensation" the material terms of which are disclosed
to and approved by stockholders. The Company has structured and intends to
implement the Amended Plan (except with respect to stock options with an
exercise price less than the fair market value of the underlying shares on the
date of grant) so that compensation resulting therefrom would be qualified
"performance-based compensation." To allow the Company to qualify such
compensation, the Company is seeking stockholder approval of the Amended Plan
and the material terms of the performance goals applicable to performance
units under the Amended Plan.
25
<PAGE>
The Amended Plan is designed to conform the Section 162(m) of the Code. With
respect to stock options awarded under the Amended Plan with an exercise price
less than the fair market value of the underlying shares on the date of grant,
there can be no assurance that the compensation attributable to such options
will not be subject to the deduction limitations of Section 162(m) of the
Code.
Section 280G of the Code
Under certain circumstances, the accelerated vesting or exercise of options
or stock appreciation rights, or the accelerated lapse of restrictions with
respect to other Awards, in connection with a Change of Control (as defined in
the Amended Plan) of the Company might be deemed an "excess parachute payment"
for purposes of the golden parachute tax provisions of Section 280G of the
Code. To the extent it is so considered, the grantee may be subject to a 20%
excise tax and the Company may be denied a tax deduction.
EFFECT ON 1986 STOCK OPTION PLAN
The adoption and approval of the Amended Plan will not affect the 1986 Plan.
Outstanding options granted under the 1986 Plan will remain in effect under
the terms of their respective grants. As of October 2, 1997, there were
3,155,740 shares of Common Stock reserved for issuance upon the exercise of
outstanding options granted under the 1986 Plan and 41,000 shares of Common
Stock available for future grants.
VOTE REQUIRED
Approval of the Amended Plan requires the affirmative vote of the holders of
a majority of the shares of Common Stock represented at the Annual Meeting, in
person or by proxy, and entitled to vote.
FOR THE REASONS STATED HEREIN, THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT STOCKHOLDERS VOTE FOR APPROVAL OF THE AMENDED PLAN.
SHAREHOLDER PROPOSALS
If a shareholder wishes to have a proposal considered for inclusion in the
Company's proxy solicitation materials in connection with the Annual Meeting
of Shareholders to be held in September 1998, the proposal must comply with
the Securities and Exchange Commission's proxy rules, be stated in writing,
and be submitted on or before June 6, 1998, to the Company at its principal
executive offices at 11440 Commerce Park Drive, Reston, Virginia 20191,
Attention: Ben Rosenbaum III, Secretary. All such proposals should be sent by
certified mail, return receipt requested.
Excluding shareholder proposals filed in accordance with the proxy rules, a
shareholder is required to comply with the Company's Bylaws with respect to
any proposal to be presented for action at an annual meeting of shareholders.
The Company's Bylaws require each proposal to be (i) written, (ii) delivered
to, or mailed and received at, the principal executive offices of the Company
not less than 60 days nor more than 90 days prior to the date of the annual
meeting, and (iii) accompanied by (A) a brief description of the proposal and
the reasons therefor, (B) the name and address of the shareholder making the
proposal and any other shareholders known by such shareholder to support such
proposal, (C) the class and number of shares of Company capital stock
beneficially owned by all such shareholders, and (D) any financial interest of
such shareholder in the proposal. If notice or public disclosure of the date
of the annual meeting occurs less than 70 days prior to the date of the annual
meeting, shareholders must deliver to the Company, or mail and have received
at the Company, the proposal and required attendant information not later than
the close of business on the tenth day following the earlier of (i) the day on
which such notice of the date of the annual meeting was mailed or (ii) the day
on which such public disclosure was made. Nothing in the Bylaws requires the
Company to include in its proxy statement and proxy for any annual meeting of
shareholders any shareholder proposal which the Company is permitted to
exclude pursuant to the rules of the Securities and Exchange Commission at the
time such proposal is received.
26
<PAGE>
If a shareholder wishes to nominate a candidate for election as director at
the Annual Meeting of Shareholders to be held in 1998, the shareholder must
comply with the Company's Bylaws with respect to director nominations. Written
notice of the shareholder's intent to make such nomination must be given to
the Secretary of the Company at the principal executive offices of the
Company, not later than 60 days prior to the date of the 1998 Annual Meeting.
The written notice shall set forth (A) the name and address of the shareholder
and each person whom the shareholder proposes to nominate as a director; (B) a
representation that the shareholder is a holder of record of stock of the
Company entitled to vote at such meeting and intends to appear in person or by
proxy at the meeting to nominate the person or persons specified in the
notice; (C) a description of all arrangements or understandings between the
shareholder and each nominee and any other person or persons (naming such
person or persons) pursuant to which the nomination or nominations are to be
made by the shareholder; (D) such other information regarding each nominee
proposed by such shareholder as would be required to be included in a proxy
statement filed pursuant to the proxy rules of the Securities and Exchange
Commission as then in effect; and (E) the consent of each nominee to serve as
a director of the Company if so elected. The presiding officer of the meeting
may refuse to acknowledge the nomination of any person not made in compliance
with the foregoing procedure.
The preceding two paragraphs are intended to summarize the applicable Bylaws
of the Company. These summaries are qualified in their entirety by reference
to those Bylaws.
SELECTION OF AUDITORS
The Board of Directors has selected Coopers & Lybrand L.L.P. to serve as the
Company's independent auditors for the current year. Coopers & Lybrand L.L.P.
has acted as the Company's independent auditors since March 17, 1995. A
representative of Coopers & Lybrand L.L.P. will be present at the Annual
Meeting of Shareholders and will have the opportunity to make a statement and
respond to any questions that might arise.
MISCELLANEOUS
The Company will bear the cost of solicitation of proxies, including
expenses in connection with the preparation and mailing of this Proxy
Statement. The Company will reimburse banks, brokers and nominees their
reasonable expenses for sending proxy material to the beneficial owners of the
Common Stock. In addition to solicitation by mail, proxies may be solicited in
person or by telephone or telegram by officers or regular employees of the
Company.
The person giving a proxy has the power to revoke it at any time before it
is exercised. All shares represented by proxies received in time to be counted
at the Annual Meeting will be voted.
Management knows of no business to be brought before the Annual Meeting of
Shareholders other than as set out above. If other matters properly come
before the meeting, it is the intention of the persons named in the solicited
proxy to vote such proxy thereon in accordance with their judgment.
Even though you plan to attend the meeting in person, please sign, date and
return the enclosed proxy promptly. If you attend the meeting, the proxy will
be voided at your request and you can vote in person. A postage-paid return-
addressed envelope is enclosed for your convenience. Your cooperation in
giving this your immediate attention will be appreciated.
By Order of the Board of Directors
Ben Rosenbaum III,
Secretary
27
<PAGE>
ANNEX A
4. The total number of shares of all classes of capital stock which the
Corporation shall have authority to issue is One Hundred Ten Million
(110,000,000) shares divided into two classes of which (i) One Hundred Million
(100,000,000) shares of par value $.01 per share shall be designated common
stock (the "Common Stock") and (ii) Ten Million (10,000,000) shares of par
value $.01 per share shall be designated preferred stock (the "Preferred
Stock").
(A) Common Stock
1. Dividends. Subject to the preferential rights, if any, of the Preferred
Stock, the holders of shares of Common Stock shall be entitled to receive,
when and if declared by the Board of Directors, out of the assets of the
Corporation which are by law available therefor, dividends payable either in
cash, in property, or in shares of Common Stock.
2. Voting Rights. At every annual or special meeting of the stockholders of
the Corporation, every holder of Common Stock shall be entitled to one vote,
in person or by proxy, for each share of Common Stock standing in his name on
the books of the Corporation.
3. Liquidation, Dissolution or Winding Up. In the event of any voluntary or
involuntary liquidation, dissolution, or winding up of the affairs of the
Corporation, after payment or provision for payment of the debts and other
liabilities of the Corporation and of the preferential amounts, if any, to
which holders of Preferred Stock shall be entitled, the holders of all
outstanding shares of Common Stock shall be entitled to share ratably in the
remaining net assets of the Corporation.
(B) Preferred Stock. The Board of Directors is authorized, subject to
limitations prescribed by law, to provide for the issuance of shares of
Preferred Stock in one or more series, to establish the number of shares to be
included in each such series, and to fix the designations, powers,
preferences, and rights of the shares of each such series, and any
qualifications, limitations or restrictions thereof. The number of authorized
shares of Preferred Stock may be increased or decreased (but not below the
number of shares thereof then outstanding) by the affirmative vote of a
majority of the votes entitled to be cast by the holders of stock of the
Corporation without the separate vote of the holders of the Preferred Stock as
a class.
Pursuant to Section 105 of the General Corporation Law of the State of
Delaware and this Certificate of Incorporation, the Board of Directors duly
adopted resolutions on July 24, 1992 to create the Series A Junior
Participating Preferred Stock, par value $.01 per share. The designation,
number of shares, the powers, relative rights, preferences, limitations and
other special rights of the Series A Junior Participating Preferred Stock are
set forth in Exhibit A to this Certificate of Incorporation.
A-1
<PAGE>
ANNEX B
PHP HEALTHCARE CORPORATION
AMENDED AND RESTATED 1996 INCENTIVE PLAN
1. Purpose. The purpose of this Plan is to strengthen PHP Healthcare
Corporation, a Delaware corporation (the "Company"), by providing an incentive
to its employees, officers, consultants and directors and thereby encouraging
them to devote their abilities and industry to the success of the Company's
business enterprise. It is intended that this purpose be achieved by extending
to employees, officers, consultants and directors of the Company and its
Subsidiaries an added long-term incentive for high levels of performance and
unusual efforts through the grant of Incentive Stock Options, Nonqualified
Stock Options, Stock Appreciation Rights, Dividend Equivalent Rights,
Performance Awards and Restricted Stock (as each term is herein defined).
2. Definitions. For purposes of the Plan:
2.1 "Adjusted Fair Market Value" means, in the event of a Change in
Control, the greater of (i) the highest price per Share paid to holders of
the Shares in any transaction (or series of transactions) constituting or
resulting in a Change in Control or (ii) the highest Fair Market Value of a
Share during the sixty (60) day period ending on the date of a Change in
Control.
2.2 "Affiliate" means any entity, directly or indirectly, controlled by,
controlling or under common control with the Company or any corporation or
other entity acquiring, directly or indirectly, all or substantially all
the assets and business of the Company, whether by operation of law or
otherwise.
2.3 "Agreement" means the written agreement between the Company and an
Optionee or Grantee evidencing the grant of an Option or Award and setting
forth the terms and conditions thereof.
2.4 "Award" means a grant of Restricted Stock, a Stock Appreciation
Right, a Performance Award, a Dividend Equivalent Right or any or all of
them.
2.5 "Board" means the Board of Directors of the Company.
2.6 "Cause" shall mean:
(a) for purposes of Section 6.4, (i) a willful act which constitutes
gross misconduct or fraud and which is materially injurious to the
Company or (ii) conviction of, or plea of "guilty" or "no contest" to,
a felony; and
(b) in all other cases, either (1) the definition set forth in the
employment agreement between the Optionee or Grantee, or in absence
thereof, (2)(i) intentional failure to perform reasonably assigned
duties, (ii) dishonesty or willful misconduct in the performance of
duties, (iii) involvement in a transaction in connection with the
performance of duties to the Company or any of its Subsidiaries which
transaction is adverse to the interests of the Company or any of its
Subsidiaries and which is engaged in for personal profit or (iv)
willful violation of any law, rule or regulation in connection with the
performance of duties (other than traffic violations or similar
offenses).
2.7 "Change in Capitalization" means any increase or reduction in the
number of Shares, or any change (including, but not limited to, a change in
value) in the Shares or exchange of Shares for a different number or kind
of shares or other securities of the Company or another corporation, by
reason of a reclassification, recapitalization, merger, consolidation,
reorganization, spin-off, split-up, issuance of warrants or rights or
debentures, stock dividend, stock split or reverse stock split, cash
dividend, property dividend, combination or exchange of shares, change in
corporate structure or substantially similar event.
2.8 A "Change in Control" shall mean the occurrence during the term of
the Plan of any of the following events:
(1) An acquisition (other than directly from the Company or pursuant
to options granted under this Plan or otherwise by the Company) of
Voting Securities by any "Person" (as the term person is used for
purposes of Section 13(d) or 14(d) of the Securities Exchange Act of
1934, as amended (the
B-1
<PAGE>
"Exchange Act")) immediately after which such Person has "Beneficial
Ownership' (within the meaning of Rule 13d-3 promulgated under the
Exchange Act) of twenty percent (20%) or more of the combined voting
power of the Company's then outstanding Voting Securities; provided,
however, that Beneficial Ownership of not more than thirty-five percent
(35%) of the combined voting power of the Company's outstanding Voting
Securities by Charles H. Robbins and/or Jack M. Mazur shall not
constitute a Change in Control; provided, further, however, in
determining whether a Change in Control has occurred, Voting Securities
which are acquired in a "Non-Control Acquisition" (as defined below)
shall not constitute an acquisition which would cause a Change in
Control. A "Non-Control Acquisition" shall mean an acquisition by (A)
an employee benefit plan (or a trust forming a part thereof) maintained
by (i) the Company or (ii) any corporation or other Person of which a
majority of its voting power or its equity securities or equity
interest is owned directly or indirectly by the Company (a "Company
Subsidiary"), (B) the Company or any Company Subsidiary, or (C) any
Person in connection with a "Non-Control Transaction" (as defined
below);
(2) The individuals who, as of October 1, 1996, are members of the
Board of Directors (the "Incumbent Board"), cease for any reason to
constitute at least two-thirds of the Board of Directors; provided,
however, that if the election, or nomination for election by the
Company's stockholders, of any new director was approved by a vote of
at least two-thirds of the Incumbent Board, such new director shall,
for purposes of the Plan, be considered as a member of the Incumbent
Board; provided, further, however, that no individual shall be
considered a member of the Incumbent Board if such individual initially
assumed office as a result of either an actual or threatened "Election
Contest" (as described in Rule 14a-11 promulgated under the Exchange
Act) or other actual or threatened solicitation of proxies or consents
by or on behalf of a Person other than the Board of Directors (a "Proxy
Contest") including by reason of any agreement intended to avoid or
settle any Election Contest or Proxy Contest; or
(3) The consummation of:
(A) A merger, consolidation or reorganization involving the
Company, unless
(i) the stockholders of the Company immediately before such
merger, consolidation or reorganization own, directly or indirectly,
immediately following such merger, consolidation or reorganization,
at least a majority of the combined voting power of the outstanding
voting securities of the corporation resulting from merger or
consolidation or reorganization (the "Surviving Corporation") in
substantially the same proportion as their ownership of the Voting
Securities immediately before such merger, consolidation or
reorganization,
(ii) the individuals who were members of the Incumbent Board
immediately prior to the execution of the agreement providing for
such merger, consolidation or reorganization constitute at least
two-thirds of the members of the board of directors of the Surviving
Corporation, or a corporation beneficially directly or indirectly
owning a majority of the Voting Securities of the Surviving
Corporation,
(iii) no Person (other than the Company or any Company Subsidiary,
any employee benefit plan (or any trust forming apart thereof)
maintained by the Company, the Surviving Corporation or any
Company's Subsidiary, or any Person who, immediately prior to such
merger, consolidation or reorganization had Beneficial Ownership of
twenty percent (20%) or more of the then outstanding Voting
Securities) has Beneficial Ownership of twenty percent (20%) or more
of the combined voting power of the Surviving Corporation's then
outstanding Voting Securities, and
(iv) a transaction described in clauses (i) through (iii) shall
herein be referred to as a "Non-Control Transaction";
(B) A complete liquidation or dissolution of the Company; or
(C) An agreement for the sale or other disposition of all or
substantially all of the assets of the Company to any Person (other
than a transfer to a Company Subsidiary).
B-2
<PAGE>
Notwithstanding the foregoing, a Change in Control shall not be deemed to
occur solely because any person (the "Subject Person") acquired Beneficial
Ownership of more than the permitted amount of the outstanding Voting
Securities as a result of the acquisition of Voting Securities by the Company
which, by reducing the number of Voting Securities outstanding, increases the
proportional number of shares beneficially owned by the Subject Person;
provided, however, that if a Change in Control would occur (but for the
operation of this sentence) as a result of the acquisition of Voting
Securities by the Company, and after such share acquisition by the Company,
the Subject Person becomes the Beneficial Owner of any additional Voting
Securities which increases the percentage of the then outstanding Voting
Securities beneficially owned by the Subject Person, then a Change in Control
shall occur.
2.9 "Code" means the Internal Revenue Code of 1986, as amended.
2.10 "Committee" means a committee, as described in Section 3.1,
appointed by the Board from time to time to administer the Plan and to
perform the functions set forth herein.
2.11 "Company" means PHP Healthcare Corporation.
2.12 "Director" means a director of the Company.
2.13 "Director Option" means an Option granted pursuant to Section 6.
2.14 "Disability" means:
(a) in the case of an Optionee or Grantee whose employment with the
Company or a Subsidiary is subject to the terms of an employment
agreement between such Optionee or Grantee and the Company or
Subsidiary, which employment agreement includes a definition of
"Disability," the term "Disability" as used in this Plan or any
Agreement shall have the meaning set forth in such employment agreement
during the period that such employment agreement remains in effect; and
(b) in all other cases, the term "Disability" as used in this Plan or
any Agreement shall mean a physical or mental infirmity which impairs
the Optionee's or Grantee's ability to perform substantially his or her
duties for a period of one hundred eighty (180) consecutive days.
2.15 "Division" means any of the operating units or divisions of the
Company designated as a Division by the Committee.
2.16 "Dividend Equivalent Right" means a right to receive all or some
portion of the cash dividends that are or would be payable with respect to
Shares.
2.17 "Eligible Director" means a director of the Company who is not an
employee of the Company or any subsidiary thereof.
2.18 "Eligible Individual" means any director (other than an Eligible
Director), officer or employee of the Company or a Subsidiary, or any
consultant or advisor who is receiving cash compensation from the Company
or a Subsidiary, designated by the Committee as eligible to receive Options
or Awards subject to the conditions set forth herein.
2.19 "Employee Option" means an Option granted pursuant to Section 5.
2.20 "Exchange Act" means the Securities Exchange Act of 1934, as
amended.
2.21 "Fair Market Value" on any date means the closing price of the
Shares on such date on the principal national securities exchange on which
such Shares are listed or admitted to trading, or, if such Shares are not
so listed or admitted to trading, the closing price on such date as quoted
on the National Association of Securities Dealers Automated Quotation
System or such other market in which such prices are regularly quoted, or,
if there have been no published bid or asked quotations with respect to
Shares on such date, the Fair Market Value shall be the value established
by the Board in good faith and, in the case of an Incentive Stock Option,
in accordance with Section 422 of the Code.
2.22 "Grantee" means a person to whom an Award has been granted under the
Plan.
2.23 "Incentive Stock Option" means an Option satisfying the requirements
of Section 422 of the Code and designated by the Committee as an Incentive
Stock Option.
B-3
<PAGE>
2.24 "Nonemployee Director" means a director of the Company who is a
"nonemployee director' within the meaning of Rule 16b-3 promulgated under
the Exchange Act.
2.25 "Nonqualified Stock Option" means an Option which is not an
Incentive Stock Option.
2.26 "Option" means a Nonqualified Stock Option, an Incentive Stock
Option, a Director Option, or any or all of them.
2.27 "Optionee" means a person to whom an Option has been granted under
the Plan.
2.28 "Outside Director" means a director of the Company who is an
"outside director' within the meaning of Section 162(m) of the Code and the
regulations promulgated thereunder.
2.29 "Parent" means any corporation which is a parent corporation (within
the meaning of Section 424(e) of the Code) with respect to the Company.
2.30 "Performance Awards" means Performance Units, Performance Shares or
either or both of them.
2.31 "Performance Cycle" means the time period specified by the Committee
at the time Performance Awards are granted during which the performance of
the Company, a Subsidiary or a Division will be measured.
2.32 "Performance Objectives" has the meaning set forth in Section 11.
2.33 "Performance Shares" means Shares issued or transferred to an
Eligible Individual under Section 11.
2.34 "Performance Units" means Performance Units granted to an Eligible
Individual under Section 11.
2.35 "Plan" means the PHP Healthcare Corporation 1996 Incentive Plan, as
amended and restated from time to time.
2.36 "Pooling Transaction" means an acquisition of the Company in a
transaction which is intended to be treated as a "pooling of interests'
under generally accepted accounting principles.
2.37 "Restricted Stock" means Shares issued or transferred to an Eligible
Individual pursuant to Section 10.
2.38 "Retirement" means termination of active employment with the Company
on or after attainment of age 62, but does not include termination by the
Company for Cause or a Voluntary Termination within the meaning of Section
12(a).
2.39 "Shares" means the common stock, par value $.01 per share, of the
Company.
2.40 "Stock Appreciation Right" means a right to receive all or some
portion of the increase in the value of the Shares as provided in Section 8
hereof.
2.41 "Subsidiary" means any corporation which is a subsidiary corporation
(within the meaning of Section 424(f) of the Code) with respect to the
Company.
2.42 "Successor Corporation" means a corporation, or a parent or
subsidiary thereof within the meaning of Section 424(a) of the Code, which
issues or assumes a stock option in a transaction to which Section 424(a)
of the Code applies.
2.43 "Ten-Percent Stockholder" means an Eligible Individual, who, at the
time an Incentive Stock Option is to be granted to him or her, owns (within
the meaning of Section 422(b)(6) of the Code) stock possessing more than
ten percent (10%) of the total combined voting power of all classes of
stock of the Company, or of a Parent or a Subsidiary.
2.44 "Termination of Employment" means the later of (i) a severance of
the employer-employee relationship with the Company or (ii) the
resignation, removal or termination of an officer of the Company.
2.45 "Voting Securities" means the combined voting power of all
outstanding voting securities entitled to vote generally in the election of
the board of directors.
B-4
<PAGE>
3. Administration.
3.1 The Plan shall be administered by the Committee, which shall hold
meetings at such times as may be necessary for the proper administration of
the Plan. The Committee shall keep minutes of its meetings. A quorum shall
consist of not fewer than two members of the Committee and a majority of a
quorum may authorize any action. Any decision or determination reduced to
writing and signed by a majority of all of the members of the Committee
shall be as fully effective as if made by a majority vote at a meeting duly
called and held. The Committee shall consist of at least two (2) directors
of the Company and may consist of the entire Board; provided, however, that
(A) if the Committee consists of less than the entire Board, each member
shall be a Nonemployee Director and (B) to the extent necessary for any
Option or Award intended to qualify as performance-based compensation under
Section 162(m) of the Code to so qualify, each member of the Committee,
whether or not it consists of the entire Board, shall be an Outside
Director. No member of the Committee shall be liable for any action,
failure to act, determination or interpretation made in good faith with
respect to this Plan or any transaction hereunder, except for liability
arising from his or her own willful misfeasance, gross negligence or
reckless disregard of his or her duties. The Company hereby agrees to
indemnify each member of the Committee for all costs and expenses and, to
the extent permitted by applicable law, any liability incurred in
connection with defending against, responding to, negotiating for the
settlement of or otherwise dealing with any claim, cause of action or
dispute of any kind arising in connection with any actions in administering
this Plan or in authorizing or denying authorization to any transaction
hereunder.
3.2 Subject to the express terms and conditions set forth herein, the
Committee shall have the power from time to time to:
(a) determine those Eligible Individuals to whom Employee Options
shall be granted under the Plan and the number of such Employee Options
to be granted and to prescribe the terms and conditions (which need not
be identical) of each such Employee Option, including the purchase
price per Share subject to each Employee Option, and make any amendment
or modification to any Option Agreement consistent with the terms of
the Plan;
(b) select those Eligible Individuals to whom Awards shall be granted
under the Plan and to determine the number of Stock Appreciation
Rights, Performance Awards, Shares of Restricted Stock and/or Dividend
Equivalent Rights to be granted pursuant to each Award, the terms and
conditions of each Award, including the restrictions or Performance
Objectives relating to Shares, the maximum value of each Performance
Share and make any amendment or modification to any Award Agreement
consistent with the terms of the Plan;
(c) to construe and interpret the Plan and the Options and Awards
granted hereunder and to establish, amend and revoke rules and
regulations for the administration of the Plan, including, but not
limited to, correcting any defect or supplying any omission, or
reconciling any inconsistency in the Plan or in any Agreement, in the
manner and to the extent it shall deem necessary or advisable so that
the Plan complies with applicable law including Rule 16b-3 under the
Exchange Act and the Code to the extent applicable, and otherwise to
make the Plan fully effective. All decisions and determinations by the
Committee in the exercise of this power shall be final, binding and
conclusive upon the Company, its Subsidiaries, the Optionees and
Grantees, and all other persons having any interest therein;
(d) to determine the duration and purposes for leaves of absence
which may be granted to an Optionee or Grantee on an individual basis
without constituting a termination of employment or service for
purposes of the Plan;
(e) to exercise its discretion with respect to the powers and rights
granted to it as set forth in the Plan; and
(f) generally, to exercise such powers and to perform such acts as
are deemed necessary or advisable to promote the best interests of the
Company with respect to the Plan.
B-5
<PAGE>
4. Stock Subject to the Plan.
4.1 The maximum number of Shares that may be made the subject of Options
and Awards granted under the Plan is 3,000,000; provided, however, that in
the aggregate, not more than one-third of the number of allotted Shares may
be made the subject of Restricted Stock Awards under Section 10 of the
Plan; and provided, further, that during the term of the Plan (i) no
Eligible Individual (other than the Chief Executive Officer) may be granted
Options and Awards (other than Performance Units denominated in Dollars) in
the aggregate in respect of more than 500,000 Shares per calendar year,
(ii) the Chief Executive Officer may not be granted Options and Awards
(other than Performance Units denominated in Dollars) in the aggregate in
respect of more than 1,000,000 Shares per calendar year, (iii) no Eligible
Individual (other than the Chief Executive Officer) may be granted
Performance Units denominated in dollars in respect of more than $2,500,000
per calendar year, (iv) the Chief Executive Officer may not be granted
Performance Units denominated in dollars in respect of more than
$10,000,000 per calendar year, and (v) the aggregate Fair Market Value of
the Shares with respect to which Incentive Stock Options granted under the
Plan become exercisable for the first time by an Optionee during any
calendar year shall not exceed the applicable Code limitation ($100,000
under Code (S) 422(d) as of the date of adoption of the Plan).
4.2 Upon the granting of an Option or an Award, the number of Shares
available under Section 4.1 for the granting of further Options and Awards
shall be reduced as follows:
(a) In connection with the granting of an Option or an Award (other
than the granting of a Performance Unit denominated in dollars), the
number of Shares shall be reduced by the number of Shares in respect of
which the Option or Award is granted or denominated.
(b) In connection with the granting of a Performance Unit denominated
in dollars, the number of Shares shall be reduced by an amount equal to
the quotient of (i) the dollar amount in which the Performance Unit is
denominated, divided by (ii) the Fair Market Value of a Share on the
date the Performance Unit is granted.
4.3 Whenever any outstanding Option or Award or portion thereof expires,
is canceled or is otherwise terminated for any reason without having been
exercised or payment having been made in respect of the entire Option or
Award, the Shares allocable to the expired, canceled or otherwise
terminated portion of the Option or Award may again be the subject of
Options or Awards granted hereunder.
5. Option Grants for Eligible Individuals.
5.1 Authority of Committee. Subject to the provisions of the Plan, the
Committee shall have full and final authority to select those Eligible
Individuals who will receive Employee Options, and the terms and conditions
of the grant to such Eligible Individuals shall be set forth in an
Agreement.
5.2 Purchase Price. The purchase price (which may be greater than, less
than or equal to the Fair Market Value on the date of grant) or the manner
in which the purchase price is to be determined for Shares under each
Employee Option shall be determined by the Committee and set forth in the
Agreement; provided, however, that the purchase price per Share under each
Incentive Stock Option shall not be less than 100% of the Fair Market Value
of a Share on the date the Employee Option is granted (110% in the case of
an Incentive Stock Option granted to a Ten-Percent Stockholder).
5.3 Maximum Duration. Employee Options granted hereunder shall be for
such term as the Committee shall determine, provided that an Incentive
Stock Option shall not be exercisable after the expiration of ten (10)
years from the date it is granted (five (5) years in the case of an
Incentive Stock Option granted to a Ten-Percent Stockholder) and a
Nonqualified Stock Option shall not be exercisable after the expiration of
ten (10) years from the date it is granted. The Committee may, subsequent
to the granting of any Employee Option, extend the term thereof, but in no
event shall the term as so extended exceed the maximum term provided for in
the preceding sentence.
5.4 Vesting. Subject to Section 7.4, each Employee Option shall become
exercisable in such installments (which need not be equal) and at such
times as may be designated by the Committee and set forth in the Agreement.
To the extent not exercised, installments shall accumulate and be
exercisable, in
B-6
<PAGE>
whole or in part, at any time after becoming exercisable, but not later
than the date the Employee Option expires. The Committee may accelerate the
exercisability of any Employee Option or portion thereof at any time.
5.5 Modification. No modification of an Employee Option shall adversely
alter or impair any rights or obligations under the Employee Option without
the Optionee's consent.
6. Option Grants for Nonemployee Directors.
6.1 Grant. Director Options shall be granted (i) to Eligible Directors
who become members of the Board after October 1, 1996 upon election or
appointment and (ii) to all Eligible Directors who are members of the Board
as follows:
(a) Initial Grant. Each Eligible Director who becomes a Director
after October 1, 1996 shall, upon becoming a Director, be granted a
Director Option in respect of 5,000 Shares.
(b) Annual Grant. Each Eligible Director shall be granted a Director
Option in respect of 5,000 Shares annually on the first business day on
or after October 24 of each calendar year that the Plan is in effect
provided that the Eligible Director is a Director on such date;
provided, however, that a Director shall not be entitled to receive an
annual grant pursuant to this Section 6.1(b) for the calendar year in
which such Director is first elected or appointed to the Board.
All Director Options shall be evidenced by an Agreement containing such
other terms and conditions not inconsistent with the provisions of this
Plan as determined by the Board; provided, however, that such terms shall
not vary the price, amount or timing of Director Options provided under
this Section 6, including provisions dealing with vesting, forfeiture and
termination of such Director Options.
6.2 Purchase Price. The purchase price for Shares under each Director
Option shall be equal to 100% of the Fair Market Value of such Shares on
the date the Director Option is granted.
6.3 Vesting. Subject to Sections 6.4 and 7.4, each Director Option shall
become fully vested and exercisable with respect to 100% of the Shares
subject thereto on the third anniversary of the date of grant; provided,
however, that the Optionee continues to serve as a Director as of such
date. If an Optionee ceases to serve as a Director for any reason, the
Optionee shall have no rights with respect to any Director Option which has
not then vested pursuant to the preceding sentence and the Optionee shall
automatically forfeit any Director Option which remains unvested.
6.4 Duration. Each Director Option shall terminate on the date which is
the tenth anniversary of the date of grant, unless terminated earlier as
follows:
(a) If an Optionee's service as a Director terminates for any reason
other than Disability, death or Cause, the Optionee may for a period of
three (3) months after such termination exercise his or her Option to
the extent, and only to the extent, that such Option or portion thereof
was vested and exercisable as of the date the Optionee's service as a
Director terminated, after which time the Option shall automatically
terminate in full.
(b) If an Optionee's service as a Director terminates by reason of
the Optionee's resignation or removal from the Board due to Disability,
the Optionee may, for a period of one (1) year after such termination,
exercise his or her Option to the extent, and only to the extent, that
such Option or portion thereof was vested and exercisable, as of the
date the Optionee's service as Director terminated, after which time
the Option shall automatically terminate in full.
(c) If an Optionee's service as a Director terminates for Cause, the
Option granted to the Optionee hereunder shall immediately terminate in
full and no rights thereunder may be exercised.
(d) If an Optionee dies while a Director or within three (3) months
after termination of service as a Director as described in clause (a)
of this Section 6.4 or within twelve (12) months after termination of
service as a Director as described in clause (b) of this Section 6.4,
the Option granted to the Optionee may be exercised at any time within
twelve (12) months after the Optionee's death by the person or
B-7
<PAGE>
persons to whom such rights under the Option shall pass by will, or by
the laws of descent or distribution, after which time the Option shall
terminate in full; provided, however, that an Option may be exercised
to the extent, and only to the extent, that the Option or portion
thereof was exercisable on the date of death or earlier termination of
the Optionee's services as a Director.
7. Terms and Conditions Applicable to All Options.
7.1 Non-Transferability. Unless set forth in the Agreement evidencing the
Option at the time of grant or at any time thereafter, an Option granted
hereunder shall not be transferable by the Optionee to whom granted except
by will or the laws of descent and distribution or pursuant to a domestic
relations order (within the meaning of Rule 16a-12 promulgated under the
Exchange Act), and an Option may be exercised during the lifetime of such
Optionee only by the Optionee or his or her guardian or legal
representative. The terms of such Option shall be final, binding and
conclusive upon the legal representatives, heirs and successors of the
Optionee.
7.2 Method of Exercise.
(a) The exercise of an Option shall be made only by a written notice
delivered in person or by mail to the Secretary of the Company at the
Company's principal executive office, specifying the number of Shares
to be purchased and accompanied by payment therefor and otherwise in
accordance with the Agreement pursuant to which the Option was granted.
The purchase price for any Shares purchased pursuant to the exercise of
an Option shall be paid, as determined by the Committee in its
discretion, in either of the following forms (or any combination
thereof): (i) cash or (ii) the transfer of Shares to the Company upon
such terms and conditions as determined by the Committee. In addition,
both Employee Options and Director Options may be exercised through a
registered broker-dealer pursuant to such cashless exercise procedures
(other than Share withholding) which are, from time to time, deemed
acceptable by the Committee. Any Shares transferred to the Company (or
withheld upon exercise) as payment of the purchase price under an
Option shall be valued at their Fair Market Value on the day preceding
the date of exercise of such Option. The Optionee shall deliver the
Agreement evidencing the Option to the Secretary of the Company who
shall endorse thereon a notation of such exercise and return such
Agreement to the Optionee. No fractional Shares (or cash in lieu
thereof) shall be issued upon exercise of an Option and the number of
Shares that may be purchased upon exercise shall be rounded to the
nearest number of whole Shares.
(b) If the Fair Market Value of the Shares with respect to which the
Option is being exercised exceeds the exercise price of such Option, an
Optionee may, instead of exercising an Option as provided in Section
7.2(a), request that the Committee authorize payment to the Optionee of
the difference between the Fair Market Value of part or all of the
Shares which are the subject of the Option and the exercise price of
the Option, such difference to be determined as of the date the
Committee receives the request from the Optionee. The Committee in its
sole discretion may grant or deny such a request from an Optionee with
respect to part or all of the Shares as to which the Option is then
exercisable and, to the extent granted, shall direct the Company to
make the payment to the Optionee either in cash or in Shares or in any
combination thereof, provided, however, that any Share shall be
distributed based upon its Fair Market Value as of the date the
Committee received the request from the Optionee. An Option shall be
deemed to have been exercised and shall be canceled to the extent that
the Committee grants a request pursuant to this Section 7.2(b).
7.3 Rights of Optionees. No Optionee shall be deemed for any purpose to
be the owner of any Shares subject to any Option unless and until (i) the
Option shall have been exercised pursuant to the terms thereof, (ii) the
Company shall have issued and delivered Shares to the Optionee, and (iii)
the Optionee's name shall have been entered as a stockholder of record on
the books of the Company. Thereupon, the Optionee shall have full voting,
dividend and other ownership rights with respect to such Shares, subject to
such terms and conditions as may be set forth in the applicable Agreement.
7.4 Effect of Change in Control. In the event of a Change in Control, all
Options outstanding on the date of such Change in Control shall become
immediately and fully exercisable. In addition, to the extent
B-8
<PAGE>
set forth in an Agreement evidencing the grant of an Employee Option, an
Optionee will be permitted to surrender to the Company for cancellation
within sixty (60) days after such Change in Control any Employee Option or
portion of an Employee Option to the extent not yet exercised and the
Optionee will be entitled to receive a cash payment in an amount equal to
the excess, if any, of (x) (A) in the case of a Nonqualified Stock Option,
the greater of (1) the Fair Market Value, on the date preceding the date of
surrender, of the Shares subject to the Employee Option or portion thereof
surrendered or (2) the Adjusted Fair Market Value of the Shares subject to
the Employee Option or portion thereof surrendered or (B) in the case of an
Incentive Stock Option, the Fair Market Value, on the date preceding the
date of surrender, of the Shares subject to the Employee Option or portion
thereof surrendered, over (y) the aggregate purchase price for such Shares
under the Employee Option or portion thereof surrendered. In the event an
Optionee's employment with, or service as a Director of, the Company is
terminated by the Company following a Change in Control, each Option held
by the Optionee that was exercisable as of the date of termination of the
Optionee's employment or service shall remain exercisable for a period
ending not before the earlier of (A) the first anniversary of the
termination of the Optionee's employment or service or (B) the expiration
of the stated term of the Option.
8. Stock Appreciation Rights. The Committee may in its discretion, either
alone or in connection with the grant of an Employee Option, grant Stock
Appreciation Rights in accordance with the Plan, the terms and conditions of
which shall be set forth in an Agreement. If granted in connection with an
Option, a Stock Appreciation Right shall cover the same Shares covered by the
Option (or such lesser number of Shares as the Committee may determine) and
shall, except as provided in this Section 8, be subject to the same terms and
conditions as the related Option.
8.1 Time of Grant. A Stock Appreciation Right may be granted (i) at any
time if unrelated to an Option, or (ii) if related to an Option, either at
the time of grant, or at any time thereafter during the term of the Option.
8.2 Stock Appreciation Right Related to an Option.
(a) Exercise. Subject to Section 8.7, a Stock Appreciation Right
granted in connection with an Option shall be exercisable at such time
or times and only to the extent that the related Options are
exercisable, and will not be transferable except to the extent the
related Option may be transferable. A Stock Appreciation Right granted
in connection with an Incentive Stock Option shall be exercisable only
if the Fair Market Value of a Share on the date of exercise exceeds the
purchase price specified in the related Incentive Stock Option
Agreement.
(b) Amount Payable. Upon the exercise of a Stock Appreciation Right
related to an Option, the Grantee shall be entitled to receive an
amount determined by multiplying (A) the excess of the Fair Market
Value of a Share on the date preceding the date of exercise of such
Stock Appreciation Right over the per Share purchase price under the
related Option, by (B) the number of Shares as to which such Stock
Appreciation Right is being exercised. Notwithstanding the foregoing,
the Committee may limit in any manner the amount payable with respect
to any Stock Appreciation Right by including such a limit in the
Agreement evidencing the Stock Appreciation Right at the time it is
granted.
(c) Treatment of Related Options and Stock Appreciation Rights Upon
Exercise. Upon the exercise of a Stock Appreciation Right granted in
connection with an Option, the Option shall be canceled to the extent
of the number of Shares as to which the Stock Appreciation Right is
exercised, and upon the exercise of an Option granted in connection
with a Stock Appreciation Right, the Stock Appreciation Right shall be
canceled to the extent of the number of Shares as to which the Option
is exercised or surrendered.
8.3 Stock Appreciation Right Unrelated to an Option. The Committee may
grant to Eligible Individuals Stock Appreciation Rights unrelated to
Options. Stock Appreciation Rights unrelated to Options shall contain such
terms and conditions as to exercisability (subject to Section 8.7), vesting
and duration as the Committee shall determine, but in no event shall they
have a term of greater than ten (10) years. Upon exercise of a Stock
Appreciation Right unrelated to an Option, the Grantee shall be entitled to
receive an
B-9
<PAGE>
amount determined by multiplying (A) the excess of the Fair Market Value of
a Share on the date preceding the date of exercise of such Stock
Appreciation Right over the Fair Market Value of a Share on the date the
Stock Appreciation Right was granted, by (B) the number of Shares as to
which the Stock Appreciation Right is being exercised. Notwithstanding the
foregoing, the Committee may limit in any manner the amount payable with
respect to any Stock Appreciation Right by including such a limit in the
Agreement evidencing the Stock Appreciation Right at the time it is
granted.
8.4 Method of Exercise. Stock Appreciation Rights shall be exercised by a
Grantee only by a written notice delivered in person or by mail to the
Secretary of the Company at the Company's principal executive office,
specifying the number of Shares with respect to which the Stock
Appreciation Right is being exercised. If requested by the Committee, the
Grantee shall deliver the Agreement evidencing the Stock Appreciation Right
being exercised and the Agreement evidencing any related Option to the
Secretary of the Company who shall endorse thereon a notation of such
exercise and return such Agreement to the Grantee.
8.5 Form of Payment. Payment of the amount determined under Sections
8.2(b) or 8.3 may be made in the discretion of the Committee solely in
whole Shares in a number determined at their Fair Market Value on the date
preceding the date of exercise of the Stock Appreciation Right, or solely
in cash, or in a combination of cash and Shares. If the Committee decides
to make full payment in Shares and the amount payable results in a
fractional Share, payment for the fractional Share will be made in cash.
8.6 Modification. No modification of an Award shall adversely alter or
impair any rights or obligations under the Agreement without the Grantee's
consent.
8.7 Effect of Change in Control. In the event of a Change in Control, all
Stock Appreciation Rights shall become immediately and fully exercisable.
In addition, to the extent set forth in an Agreement evidencing the grant
of a Stock Appreciation Right, a Grantee will be entitled to receive a
payment from the Company in cash or stock, in either case, with a value
equal to the excess, if any, of (A) the greater of (x) the Fair Market
Value, on the date preceding the date of exercise, of the underlying Shares
subject to the Stock Appreciation Right or portion thereof exercised and
(y) the Adjusted Fair Market Value, on the date preceding the date of
exercise, of the Shares over (B) the aggregate Fair Market Value, on the
date the Stock Appreciation Right was granted, of the Shares subject to the
Stock Appreciation Right or portion thereof exercised. In the event a
Grantee's employment with the Company is terminated by the Company
following a Change in Control each Stock Appreciation Right held by the
Grantee that was exercisable as of the date of termination of the Grantee's
employment shall remain exercisable for a period ending not before the
earlier of (A) the first anniversary of the termination of the Grantee's
employment or (B) the expiration of the stated term of the Stock
Appreciation Right.
9. Dividend Equivalent Rights. Dividend Equivalent Rights may be granted to
Eligible Individuals in tandem with an Option or Award. The terms and
conditions applicable to each Dividend Equivalent Right shall be specified in
the Agreement under which the Dividend Equivalent Right is granted. Amounts
payable in respect of Dividend Equivalent Rights may be payable currently or
deferred until the lapsing of restrictions on such Dividend Equivalent Rights
or until the vesting, exercise, payment, settlement or other lapse of
restrictions on the Option or Award to which the Dividend Equivalent Rights
relate. In the event that the amount payable in respect of Dividend Equivalent
Rights are to be deferred, the Committee shall determine whether such amounts
are to be held in cash or reinvested in Shares or deemed (notionally) to be
reinvested in Shares. If amounts payable in respect of Dividend Equivalent
Rights are to be held in cash, there may be credited at the end of each year
(or portion thereof) interest on the amount of the account at the beginning of
the year at a rate per annum as the Committee, in its discretion, may
determine. Dividend Equivalent Rights may be settled in cash or Shares or a
combination thereof, in a single installment or multiple installments.
10. Restricted Stock.
10.1 Grant. The Committee may grant Awards to Eligible Individuals of
Restricted Stock, which shall be evidenced by an Agreement between the
Company and the Grantee. Each Agreement shall contain
B-10
<PAGE>
such restrictions, terms and conditions as the Committee may, in its
discretion, determine and (without limiting the generality of the
foregoing) such Agreements may require that an appropriate legend be placed
on Share certificates. Awards of Restricted Stock shall be subject to the
terms and provisions set forth below in this Section 10.
10.2 Rights of Grantee. Shares of Restricted Stock granted pursuant to an
Award hereunder shall be issued in the name of the Grantee as soon as
reasonably practicable after the Award is granted provided that the Grantee
has executed an Agreement evidencing the Award, the appropriate blank stock
powers and, in the discretion of the Committee, an escrow agreement and any
other documents which the Committee may require as a condition to the
issuance of such Shares. If a Grantee shall fail to execute the Agreement
evidencing a Restricted Stock Award, the appropriate blank stock powers
and, in the discretion of the Committee, an escrow agreement and any other
documents which the Committee may require within the time period prescribed
by the Committee at the time the Award is granted, the Award shall be null
and void. At the discretion of the Committee, Shares issued in connection
with a Restricted Stock Award shall be deposited together with the stock
powers with an escrow agent (which may be the Company) designated by the
Committee. Unless the Committee determines otherwise and as set forth in
the Agreement, upon delivery of the Shares to the escrow agent, the Grantee
shall have all of the rights of a stockholder with respect to such Shares,
including the right to vote the Shares and to receive all dividends or
other distributions paid or made with respect to the Shares.
10.3 Non-transferability. Until all restrictions upon the Shares of
Restricted Stock awarded to a Grantee shall have lapsed in the manner set
forth in Section 10.4, such Shares shall not be sold, transferred or
otherwise disposed of and shall not be pledged or otherwise hypothecated,
nor shall they be delivered to the Grantee.
10.4 Lapse of Restrictions.
(a) Generally. Restrictions upon Shares of Restricted Stock awarded
hereunder shall lapse at such time or times and on such terms and
conditions as the Committee may determine. The Agreement evidencing the
Award shall set forth any such restrictions.
(b) Effect of Change in Control. Unless the Committee shall determine
otherwise at the time of the grant of an Award of Restricted Stock, the
restrictions upon Shares of Restricted Stock shall lapse upon a Change
in Control. The Agreement evidencing the Award shall set forth any such
provisions.
10.5 Modification or Substitution. Subject to the terms of the Plan, the
Committee may modify outstanding Awards of Restricted Stock or accept the
surrender of outstanding Shares of Restricted Stock (to the extent the
restrictions on such Shares have not yet lapsed) and grant new Awards in
substitution for them. Notwithstanding the foregoing, no modification of an
Award shall adversely alter or impair any rights or obligations under the
Agreement without the Grantee's consent.
10.6 Treatment of Dividends. At the time an Award of Shares of Restricted
Stock is granted, the Committee may, in its discretion, determine that the
payment to the Grantee of dividends, or a specified portion thereof,
declared or paid on such Shares by the Company shall be (i) deferred until
the lapsing of the restrictions imposed upon such Shares and (ii) held by
the Company for the account of the Grantee until such time. In the event
that dividends are to be deferred, the Committee shall determine whether
such dividends are to be reinvested in shares of Stock (which shall be held
as additional Shares of Restricted Stock) or held in cash. If deferred
dividends are to be held in cash, there may be credited at the end of each
year (or portion thereof) interest on the amount of the account at the
beginning of the year at a rate per annum as the Committee, in its
discretion, may determine. Payment of deferred dividends in respect of
Shares of Restricted Stock (whether held in cash or as additional Shares of
Restricted Stock), together with interest accrued thereon, if any, shall be
made upon the lapsing of restrictions imposed on the Shares in respect of
which the deferred dividends were paid, and any dividends deferred
(together with any interest accrued thereon) in respect of any Shares of
Restricted Stock shall be forfeited upon the forfeiture of such Shares.
B-11
<PAGE>
10.7 Delivery of Shares. Upon the lapse of the restrictions on Shares of
Restricted Stock, the Committee shall cause a stock certificate to be
delivered to the Grantee with respect to such Shares, free of all
restrictions hereunder.
11. Performance Awards.
11.1 (a) Performance Objectives. Performance Objectives for Performance
Awards may be expressed in terms of (i) earnings per Share, (ii) Share
price, (iii) pre-tax profits, (iv) net earnings, (v) return on equity or
assets, (vi) revenues, (vii) EBITDA, (viii) market share or market
penetration or (ix) any combination of the foregoing, and may be determined
before or after accounting changes, special charges, foreign currency
effects, acquisitions, divestitures or other extraordinary events.
Performance Objectives may be in respect of the performance of the Company
and its Subsidiaries (which may be on a consolidated basis), a Subsidiary
or a Division. Performance Objectives may be absolute or relative and may
be expressed in terms of a progression within a specified range. The
Performance Objectives with respect to a Performance Cycle shall be
established in writing by the Committee by the earlier of (i) the date on
which a quarter of the Performance Cycle has elapsed or (ii) the date which
is ninety (90) days after the commencement of the Performance Cycle, and in
any event while the performance relating to the Performance Objectives
remain, substantially uncertain.
(b) Determination of Performance. Prior to the vesting, payment,
settlement or lapsing of any restrictions with respect to any Performance
Award made to a Grantee who is subject to Section 162(m) of the Code, the
Committee shall certify in writing that the applicable Performance
Objectives have been satisfied.
11.2 Performance Units. The Committee, in its discretion, may grant
Awards of Performance Units to Eligible Individuals, the terms and
conditions of which shall be set forth in an Agreement between the Company
and the Grantee. Performance Units shall be denominated in Shares or a
specified dollar amount and, contingent upon the attainment of specified
Performance Objectives within the Performance Cycle, represent the right to
receive payment as provided in Section 11.2(b) of the specified dollar
amount or a percentage (which may be more than 100%) thereof depending on
the level of Performance Objective attainment; provided, however, that, the
Committee may at the time a Performance Unit is granted specify a maximum
amount pay able in respect of a vested Performance Unit. Each Agreement
shall specify either a fixed number of Performance Units to which it
relates or a formula pursuant to which the number of Performance Units may
be calculated, the Performance Objectives which must be satisfied in order
for the Performance Units to vest and the Performance Cycle within which
such Performance Objectives must be satisfied.
(a) Vesting and Forfeiture. Subject to Sections 11.1(b) and 11.4, a
Grantee shall become vested with respect to the Performance Units to
the extent that the Performance Objectives set forth in the Agreement
are satisfied for the Performance Cycle.
(b) Payment of Awards. Payment to Grantees in respect of vested
Performance Units shall be made as soon as practicable after the last
day of the Performance Cycle to which such Award relates unless the
Agreement evidencing the Award provides for the deferral of payment, in
which event the terms and conditions of the deferral shall be set forth
in the Agreement. Subject to Section 11.4, such payments may be made
entirely in Shares valued at their Fair Market Value as of the last day
of the applicable Performance Cycle or such other date specified by the
Committee, entirely in cash, or in such combination of Shares and cash
as the Committee in its discretion shall determine at any time prior to
such payment; provided, however, that if the Committee in its
discretion determines to make such payment entirely or partially in
Shares of restricted stock, the Committee must determine the extent to
which such payment will be in Shares of restricted stock and the terms
of such restricted stock at the time the Award is granted.
11.3 Performance Shares. The Committee, in its discretion, may grant
Awards of Performance Shares to Eligible Individuals, the terms and
conditions of which shall be set forth in an Agreement between
B-12
<PAGE>
the Company and the Grantee. Each Agreement may require that an appropriate
legend be placed on Share certificates. Awards of Performance Shares shall
be subject to the following terms and provisions:
(a) Rights of Grantee. The Committee shall provide at the time an
Award of Performance Shares is made the time or times at which the
actual Shares represented by such Award shall be issued in the name of
the Grantee; provided, however, that no Performance Shares shall be
issued until the Grantee has executed an Agreement evidencing the
Award, the appropriate blank stock powers and, in the discretion of the
Committee, an escrow agreement and any other documents which the
Committee may require as a condition to the issuance of such
Performance Shares. If a Grantee shall fail to execute the Agreement
evidencing an Award of Performance Shares, the appropriate blank stock
powers and, in the discretion of the Committee, an escrow agreement and
any other documents which the Committee may require within the time
period prescribed by the Committee at the time the Award is granted,
the Award shall be null and void. At the discretion of the Committee,
Shares issued in connection with an Award of Performance Shares shall
be deposited together with the stock powers with an escrow agent (which
may be the Company) designated by the Committee. Except as restricted
by the terms of the Agreement, upon delivery of the Shares to the
escrow agent, the Grantee shall have, in the discretion of the
Committee, all of the rights of a stockholder with respect to such
Shares, including the right to vote the Shares and to receive all
dividends or other distributions paid or made with respect to the
Shares.
(b) Non-transferability. Until any restrictions upon the Performance
Shares awarded to a Grantee shall have lapsed in the manner set forth
in Sections 11.3(c) or 11.4, such Performance Shares shall not be sold,
transferred or otherwise disposed of and shall not be pledged or
otherwise hypothecated, nor shall they be delivered to the Grantee. The
Committee may also impose such other restrictions and conditions on the
Performance Shares, if any, as it deems appropriate.
(c) Lapse of Restrictions. Subject to Sections 11.1(b) and 11.4,
restrictions upon Performance Shares awarded hereunder shall lapse and
such Performance Shares shall become vested at such time or times and
on such terms, conditions and satisfaction of Performance Objectives as
the Committee may, in its discretion, determine at the time an Award is
granted.
(d) Treatment of Dividends. At the time the Award of Performance
Shares is granted, the Committee may, in its discretion, determine that
the payment to the Grantee of dividends, or a specified portion
thereof, declared or paid on actual Shares represented by such Award
which have been issued by the Company to the Grantee shall be (i)
deferred until the lapsing of the restrictions imposed upon such
Performance Shares and (ii) held by the Company for the account of the
Grantee until such time. In the event that dividends are to be
deferred, the Committee shall determine whether such dividends are to
be reinvested in shares of Stock (which shall be held as additional
Performance Shares) or held in cash. If deferred dividends are to be
held in cash, there may be credited at the end of each year (or portion
thereof) interest on the amount of the account at the beginning of the
year at a rate per annum as the Committee, in its discretion, may
determine. Payment of deferred dividends in respect of Performance
Shares (whether held in cash or in additional Performance Shares),
together with interest accrued thereon, if any, shall be made upon the
lapsing of restrictions imposed on the Performance Shares in respect of
which the deferred dividends were paid, and any dividends deferred
(together with any interest accrued thereon) in respect of any
Performance Shares shall be forfeited upon the forfeiture of such
Performance Shares.
(e) Delivery of Shares. Upon the lapse of the restrictions on
Performance Shares awarded the Committee shall cause a stock
certificate to be delivered to the Grantee, free of all restrictions
hereunder.
11.4 Effect of Change in Control. In the event of a Change in Control:
(a) With respect to Performance Units, unless otherwise determined by
the Committee, the Grantee shall (i) become vested in all Performance
Units and (ii) be entitled to receive in respect of all Performance
Units which become vested as a result of a Change in Control a cash
payment within ten
B-13
<PAGE>
(10) days after such Change in Control in an amount as determined by
the Committee at the time of the Award of such Performance Unit and as
set forth in the Agreement.
(b) With respect to Performance Shares, unless otherwise determined
by the Committee, restrictions shall lapse immediately on all
Performance Shares.
(c) The Agreements evidencing Performance Shares and Performance
Units shall provide for the treatment of such Awards (or portions
thereof) which do not become vested as the result of a Change in
Control, including, but not limited to, provisions for the adjustment
of applicable Performance Objectives.
11.5 Modification or Substitution. Subject to the terms of the Plan, the
Committee may modify outstanding Performance Awards or accept the surrender
of outstanding Performance Awards and grant new Performance Awards in
substitution for them. Notwithstanding the foregoing, no modification of a
Performance Award shall adversely alter or impair any rights or obligations
under the Agreement without the Grantee's consent.
12. Effect of a Termination of Employment. An employment agreement, if
applicable, between an Optionee or Grantee and the Company shall govern with
respect to the terms and conditions applicable to such Option or Award upon a
termination or change in the status of the employment of the Optionee or
Grantee. However, in absence of an employment agreement, the following shall
apply:
(a) The Agreement evidencing the grant of each Option and each Award
shall set forth the terms and conditions applicable to such Option or Award
upon a termination or change in the status of the employment of the
Optionee or Grantee by the Company, a Subsidiary or a Division (including a
termination or change by reason of the sale of a Subsidiary or a Division),
which, except for Director Options, shall be as the Committee may, in its
discretion, determine at the time the Option or Award is granted or
thereafter.
(b) Unless otherwise determined by the Committee at the time of grant
(and set forth in the Option Agreement) or at a later date, except in the
case of death, Disability and Retirement as provided in paragraphs 12(c)
and 12(d) below, if an Optionee of an Employee Option granted under the
Plan has a Termination of Employment with the Company or a Subsidiary, any
unexercised Employee Option held by such Optionee shall expire ninety (90)
days after the Optionee has a Termination of Employment for any reason
other than a termination for Cause or a Voluntary Termination (as defined
below), and such Employee Option may only be exercised by the Optionee or
his Beneficiary to the extent that the Employee Option or a portion thereof
was exercisable on the date of Termination of Employment; provided,
however, no Employee Option may be exercised after the expiration date
specified for the particular Employee Option in the Employee Option grant.
If the Optionee's Termination of Employment arises as a result of a
termination for Cause or a Voluntary Termination, then, unless the
Committee determines otherwise at the time of the Termination of
Employment, any unexercised Options held by such Optionee shall terminate
and expire concurrently with the Optionee's Termination of Employment. A
"Voluntary Termination" shall mean the voluntary Termination of Employment
by an Optionee prior to five years of total Service (as defined below) as
an employee with the Company and its Subsidiaries. "Service" shall mean
total of years for which the Optionee, prior to or after first becoming an
Optionee, has 1,000 hours of service as an employee or otherwise with, or
has served as a director or officer of, the Company or a Subsidiary.
(c) Unless otherwise determined by the Committee at the time of grant
(and set forth in the Option Agreement) or at a later date, if an Optionee
dies while still employed by the Company, the shares which the Optionee was
entitled to exercise on the date of the Optionee's death under an Option or
Options granted under the Plan may be exercised at any time after the
Optionee's death by the Optionee's beneficiary; provided, however, that no
Option may be exercised after the earlier of: (i) one (1) year after the
Optionee's death or (ii) the expiration date specified for the particular
Option in the Option Agreement.
(d) Unless otherwise determined by the Committee at the time of grant
(and set forth in the Option Agreement) or at a later date, if an Optionee
becomes disabled within the meaning of Section 2.14 hereof or has a
Termination of Employment because of Retirement, any unexercised Employee
Option held by such disabled or retired Optionee shall expire one (1) year
after the Optionee has a Termination of
B-14
<PAGE>
Employment because of such Disability or Retirement and such Option may
only be exercised by the Optionee or his Beneficiary to the extent that the
Employee Option or a portion thereof was exercisable on the date of
Termination of Employment because of such Disability or Retirement;
provided, however, no Employee Option may be exercised after the expiration
date specified for the particular Employee Option in the Employee Option
grant.
13. Adjustment Upon Changes in Capitalization.
(a) In the event of a Change in Capitalization, the Committee shall
conclusively determine the appropriate adjustments, if any, to (i) the
maximum number and class of Shares or other stock or securities with
respect to which Options or Awards may be granted under the Plan, (ii) the
maximum number and class of Shares or other stock or securities with
respect to which Options or Awards may be granted to any Eligible
Individual during the term of the Plan, (iii) the number and class of
Shares or other stock or securities which are subject to outstanding
Options or Awards granted under the Plan and the purchase price therefor,
if applicable, (iv) the number and class of Shares or other securities in
respect of which Director Options are to be granted under Section 6 and (v)
the Performance Objectives.
(b) Any such adjustment in the Shares or other stock or securities
subject to outstanding Incentive Stock Options (including any adjustments
in the purchase price) shall be made in such manner as not to constitute a
modification as defined by Section 424(h)(3) of the Code and only to the
extent otherwise permitted by Sections 422 and 424 of the Code.
(c) If, by reason of a Change in Capitalization, a Grantee of an Award
shall be entitled to, or an Optionee shall be entitled to exercise an
Option with respect to, new, additional or different shares of stock or
securities, such new, additional or different shares shall thereupon be
subject to all of the conditions, restrictions and performance criteria
which were applicable to the Shares subject to the Award or Option, as the
case may be, prior to such Change in Capitalization.
14. Effect of Certain Transactions. Subject to Sections 7.4, 8.7, 10.4(b)
and 11.4 or as otherwise provided in an Agreement, in the event of (i) the
liquidation or dissolution of the Company or (ii) a merger or consolidation of
the Company (a "Transaction"), the Plan and the Options and Awards issued
hereunder shall continue in effect in accordance with their respective terms,
except that following a Transaction each Optionee and Grantee shall be
entitled to receive in respect of each Share subject to any outstanding
Options or Awards, as the case may be, upon exercise of any Option or payment
or transfer in respect of any Award, the same number and kind of stock,
securities, cash, property or other consideration that each holder of a Share
was entitled to receive in the Transaction in respect of a Share; provided,
however, that such stock, securities, cash, property, or other consideration
shall remain subject to all of the conditions, restrictions and performance
criteria which were applicable to the Options and Awards prior to such
Transaction.
15. Interpretation. Following the required registration of any equity
security of the Company pursuant to Section 12 of the Exchange Act:
(a) The Plan is intended to comply with Rule 16b-3 promulgated under the
Exchange Act and the Committee shall interpret and administer the
provisions of the Plan or any Agreement in a manner consistent therewith.
Any provisions inconsistent with such Rule shall be inoperative and shall
not affect the validity of the Plan.
(b) Unless otherwise expressly stated in the relevant Agreement, each
Option, Stock Appreciation Right and Performance Award granted under the
Plan is intended to be performance-based compensation within the meaning of
Section 162(m)(4)(C) of the Code. The Committee shall not be entitled to
exercise any discretion otherwise authorized hereunder with respect to such
Options or Awards if the ability to exercise such discretion or the
exercise of such discretion itself would cause the compensation
attributable to such Options or Awards to fail to qualify as performance-
based compensation.
16. Pooling Transactions. Notwithstanding anything contained in the Plan or
any Agreement to the contrary, in the event of a Change in Control which is
also intended to constitute a Pooling Transaction, the
B-15
<PAGE>
Committee shall take such actions, if any, as are specifically recommended by
an independent accounting firm retained by the Company to the extent
reasonably necessary in order to assure that the Pooling Transaction will
qualify as such, including but not limited to (i) deferring the vesting,
exercise, payment, settlement or lapsing of restrictions with respect to any
Option or Award, (ii) providing that the payment or settlement in respect of
any Option or Award be made in the form of cash, Shares or securities of a
successor or acquirer of the Company, or a combination of the foregoing, and
(iii) providing for the extension of the term of any Option or Award to the
extent necessary to accommodate the foregoing, but not beyond the maximum term
permitted for any Option or Award.
17. Effective Date, Termination and Amendment of the Plan. The effective
date of this Plan shall be the date the Plan is adopted by the Board, subject
only to the approval by the affirmative vote of the holders of a majority of
the securities of the Company present, or represented, and entitled to vote at
a meeting of stockholders duly held in accordance with the applicable laws of
the State of Delaware within twelve (12) months of the adoption of the Plan by
the Board.
The Plan shall terminate on the day preceding the tenth anniversary of the
date of its adoption by the Board and no Option or Award may be granted
thereafter. The Board may sooner terminate the Plan and the Board may at any
time and from time to time amend, modify or suspend the Plan; provided,
however, that: (a) no such amendment, modification, suspension or termination
shall impair or adversely alter any Options or Awards theretofore granted
under the Plan, except with the consent of the Optionee or Grantee, nor shall
any amendment, modification, suspension or termination deprive any Optionee or
Grantee of any Shares which he or she may have acquired through or as a result
of the Plan; and (b) to the extent necessary under applicable law, no
amendment shall be effective unless approved by the stockholders of the
Company in accordance with applicable law.
18. Non-Exclusivity of the Plan. The adoption of the Plan by the Board shall
not be construed as amending, modifying or rescinding any previously approved
incentive arrangement or as creating any limitations on the power of the Board
to adopt such other incentive arrangements as it may deem desirable,
including, without limitation, the granting of stock options otherwise than
under the Plan, and such arrangements may be either applicable generally or
only in specific cases.
19. Limitation of Liability. As illustrative of the limitations of liability
of the Company, but not intended to be exhaustive thereof, nothing in the Plan
shall be construed to:
(i) give any person any right to be granted an Option or Award other than
at the sole discretion of the Committee;
(ii) give any person any rights whatsoever with respect to Shares except
as specifically provided in the Plan;
(iii) limit in any way the right of the Company to terminate the
employment of any person at any time; or
(iv) be evidence of any agreement or understanding, expressed or implied,
that the Company will employ any person at any particular rate of
compensation or for any particular period of time.
20. Regulations and Other Approvals; Governing Law.
20.1 Except as to matters of federal law, the Plan and the rights of all
persons claiming hereunder shall be construed and determined in accordance
with the laws of the State of Delaware without giving effect to conflicts
of laws principles thereof.
20.2 The obligation of the Company to sell or deliver Shares with respect
to Options and Awards granted under the Plan shall be subject to all
applicable laws, rules and regulations, including all applicable federal
and state securities laws, and the obtaining of all such approvals by
governmental agencies as may be deemed necessary or appropriate by the
Committee.
20.3 The Board may make such changes as may be necessary or appropriate
to comply with the rules and regulations of any government authority, or to
obtain for Eligible Individuals granted Incentive Stock
B-16
<PAGE>
Options the tax benefits under the applicable provisions of the Code and
regulations promulgated thereunder.
20.4 Each Option and Award is subject to the requirement that, if at any
time the Committee determines, in its discretion, that the listing,
registration or qualification of Shares issuable pursuant to the Plan is
required by any securities exchange or under any state or federal law, or
the consent or approval of any governmental regulatory body is necessary or
desirable as a condition of, or in connection with, the grant of an Option
or Award or the issuance of Shares, no Options or Awards shall be granted
or payment made or Shares issued, in whole or in part, unless listing,
registration, qualification, consent or approval has been effected or
obtained free of any conditions as acceptable to the Committee.
20.5 Notwithstanding anything contained in the Plan or any Agreement to
the contrary, in the event that the disposition of Shares acquired pursuant
to the Plan is not covered by a then current registration statement under
the Securities Act of 1933, as amended (the "Securities Act"), and is not
otherwise exempt from such registration, such Shares shall be restricted
against transfer to the extent required by the Securities Act and Rule 144
or other regulations thereunder. The Committee may require any individual
receiving Shares pursuant to an Option or Award granted under the Plan, as
a condition precedent to receipt of such Shares, to represent and warrant
to the Company in writing that the Shares acquired by such individual are
acquired without a view to any distribution thereof and will not be sold or
transferred other than pursuant to an effective registration thereof under
said Act or pursuant to an exemption applicable under the Securities Act or
the rules and regulations promulgated thereunder. The certificates
evidencing any of such Shares shall be appropriately amended to reflect
their status as restricted securities as aforesaid.
21. Miscellaneous.
21.1 Multiple Agreements. The terms of each Option or Award may differ
from other Options or Awards granted under the Plan at the same time, or at
some other time. The Committee may also grant more than one Option or Award
to a given Eligible Individual during the term of the Plan, either in
addition to, or in substitution for, one or more Options or Awards
previously granted to that Eligible Individual.
21.2 Withholding of Taxes.
(a) At such times as an Optionee or Grantee recognizes taxable income
in connection with the receipt of Shares or cash hereunder (a "Taxable
Event"), the Optionee or Grantee shall pay to the Company an amount
equal to the federal, state and local income taxes and other amounts as
may be required by law to be withheld by the Company in connection with
the Taxable Event (the "Withholding Taxes") prior to the issuance, or
release from escrow, of such Shares or the payment of such cash. The
Company shall have the right to deduct from any payment of cash to an
Optionee or Grantee an amount equal to the Withholding Taxes in
satisfaction of the obligation to pay Withholding Taxes. In
satisfaction of the obligation to pay Withholding Taxes to the Company,
the Optionee or Grantee may make a written election (the "Tax
Election"), which may be accepted or rejected in the discretion of the
Committee, to have withheld a portion of the Shares then issuable to
him or her having an aggregate Fair Market Value equal to the
Withholding Taxes.
(b) If an Optionee makes a disposition, within the meaning of Section
424(c) of the Code and regulations promulgated thereunder, of any Share
or Shares issued to such Optionee pursuant to the exercise of an
Incentive Stock Option within the two-year period commencing on the day
after the date of the grant or within the one-year period commencing on
the day after the date of transfer of such Share or Shares to the
Optionee pursuant to such exercise, the Optionee shall, within ten (10)
days of such disposition, notify the Company thereof, by delivery of
written notice to the Company at its principal executive office.
B-17
<PAGE>
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE FOLLOWING:
I. Election of Directors FOR all nominees WITHHOLD AUTHORITY to vote
listed below / / for all nominees listed
below / /
*EXCEPTIONS / /
Nominee: For terms ending in 2000 -- Jerry W. Carlton, William J. Lubin, John
J. McDonnell and Charles P. Reilly
(INSTRUCTIONS: TO WITHHOLD AUTHORITY TO VOTE FOR ANY INDIVIDUAL NOMINEE, MARK
THE "EXCEPTIONS" BOX AND WRITE THAT NOMINEE'S NAME IN THE SPACE PROVIDED BELOW.)
*Exceptions: __________________________________________________________
II. To approve the amendments to the Certificate of Incorporation
FOR / / AGAINST / / ABSTAIN / /
III. To approve the PHP Healthcare Corporation Amended and Restated 1996
Incentive Plan.
FOR / / AGAINST / / ABSTAIN / /
In their discretion, the Proxies are authorized to vote upon such other business
as may properly come before the meeting.
Change of Address and
or Comments Mark Here / /
Please sign exactly as name appears on the label affixed hereto. When signing
as attorney, executor, administrator, trustee or guardian, please give full
title. If more than one trustee, all should sign.
Dated: ___________________________ 1997
_____________________________________
Signature
_____________________________________
SIGN, DATE AND RETURN THIS CARD PROMPTLY USING THE ENCLOSED ENVELOPE.
VOTES MUST BE INDICATED
(X) IN BLACK OR BLUE INK. / /
<PAGE>
PHP HEALTHCARE CORPORATION
PROXY FOR 1997 ANNUAL MEETING OF SHAREHOLDERS
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The undersigned appoints Jack M. Mazur and Michael D. Starr, or either of
them (with full power to act alone), as proxies for the undersigned with full
power of substitution, to vote all the shares of Common Stock of PHP Healthcare
Corporation standing in the undersigned's name on its books at the close of
business on October 2, 1997 at the Annual Meeting of Shareholders to be held at
the Company's corporate offices at 11440 Commerce Park Drive, Reston, Virginia
on November 3, 1997, at 10:00 a.m., local time, and at any adjournment thereof,
with all the powers the undersigned would possess if personally present, as
indicated on the reverse side.
This proxy when properly executed will be voted in the manner directed
herein by the undersigned shareholder. The undersigned hereby acknowledges
receipt of Notice of said Annual Meeting dated October 8, 1997, and accompanying
Proxy Statement.
If no direction is made, this proxy will be voted FOR Proposals I, II and
III.
(Continued and to be SIGNED on reverse side)
PHP HEALTHCARE CORPORATION
P.O. BOX 11051
NEW YORK, N.Y. 10203-0051
